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ABSTRACT
CASPASE-7 LOOP CONFORMATIONS AS A MEANS OF ALLOSTERIC
CONTROL
MAY 2011
WITOLD WITKOWSKI, B.S. COLLEGE OF CHARLESTON
Ph.D. UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jeanne A. Hardy
The caspase family of proteins is critical to biological understanding, because they serve
as the final arbiters of life and death, being the initiators and executioners of cell death.
Specifically, caspase-7 plays a key role in apoptosis, however its full complement of
targets within the cell has not yet been elucidated, nor has its function been targeted by
drug design efforts. These factors stem from the lack of fundamental understanding of the
structural dynamics of the protein, including the mobile loops that constitute the active
site binding groove of caspase-7, and their ability to modulate the function of the protein.
In this work, we describe the importance of the entire loop bundle for catalysis,
demonstrate a novel approach for allosteric control using loop movement, develop
computational methods to engineer a new binding site for an allosteric effector and
discover a hereunto unseen native disulfide within caspase-7 that may contribute to
specificity and catalysis. The information obtained within this study is applicable for not
only the study of caspase-7, but also the greater field of apoptosis research.
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CHAPTER I

INTRODUCTION
The ability to dynamically and independently modulate the function of proteins for either
elucidative reasons or curative treatments would change the world of medicine. Advances
in structural biochemistry, combined with novel techniques will allow new problems to
be tackled. In this work, I present advancements in the field of protein chemistry that
develop new insights into the role of the loops in caspase-7, and their ability to control
caspase-7.

Apoptosis
For many years, it was tacitly assumed that due to continuous cellular
proliferation, a mechanism for programmed cell death must exist. Until cell morphologies
during cell death were rigorously defined, programmed cell death was broadly described
as coagulative necrosis active site1. The morphological changes in two types of cell
death, necrosis and apoptosis, lead to the distinction in the classes. During necrosis, cells
swell and burst, leaving cellular debris, which often results in an inflammatory response.
Conversely, apoptosing cells shrink, and are rapidly phagocytosed in an orderly fashion.
Since Kerr and coworkers coined the term apoptosis in their seminal 1972 paper, the
highly conserved cellular machinery responsible for this ordered process has been
broadly studied across many organisms, and its evolutionarily conserved pathways have
been elucidated.
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Apoptosis’ importance to cellular function and organism development cannot be
understated, its regulation is necessary for both death, and life in cells. Apoptosis is most
associated with cellular demise, however regulated cell death is necessary for proper
organism development. For instance, in mice deficient a cell death protein (caspase-3),
organism death occurs early in embryonic development with an over abundance of
neuroepithelial cells2. This suggests that cell death is necessary in neurological
development. In another experiment, irreversible broad spectrum peptidic inhibitors of
apoptosis were introduced into chicken embryos, and the footpads were studied3. In
embryos treated with the inhibitors, evidence of interdigital cell death decreased, leaving
the embryo with webbed feet (Figure 1). The role of apoptosis is not limited to limb
development, as many have shown that regulated cell death plays a key role in sexual
differentiation4-7, and terminal cell differentiation. A erythrocyte’s final developmental
stage involves the loss of organelles and nucleus, but remain viable and continue to
metabolize; conversely keratinocytes form layers of squamous skin layers at their final
differentiation stage. These two near end of life or alternate G1 exit stage processes are
thought to be the result of modified programmed cell death8,9.

2

Figure 1: Inhibition of apoptosis in development.
Interdigital cell death (dark staining, arrows) is retarded in the presence of apoptotic inhibitors3.

Disorders Associated with Apoptosis
Apoptosis’s role in the life/death decision is critical, and cellular havoc occurs when
apoptosis goes wrong. Errors in apoptosis have been linked to many diseases, as the
delicate life/death balance is disturbed. During cell proliferation, a number of regulators
and growth factors check the cell cycle to maintain order10. The disease most classically
associated with down-regulated cell death is cancer. Though there exist many variants of
malignancy, all stem from a common inability to undergo apoptosis11. Disorders typically
associated with rapid cell death are heart attacks and stroke. Notably, these diseases are
primarily caused by lack of blood flow to the region, leading the affected cells to necrose.
However, tissue not directly affected by the restricted blood flow, but in the vicinity of
necrotic tissue has been shown to die by apoptosis12,13, and directly inhibiting apoptosis
in these cells can limit the damage14. Less obvious diseases such as viral infections and
their associated cellular processes have also been linked to apoptosis15,16.

Caspases
The amazing molecular scale machinery that is responsible for executing the balance of
life and death in cells are called caspases, from Cysteine-Aspartate-Proteases. The origin
of caspases and their role in the apoptotic pathway was first reported by Robert Horvitz
and coworkers, while studying the C. elegans death gene CED-317. Horvitz was
subsequently awarded the Nobel Prize for the elucidation of the apoptotic pathway.
Horvitz and coworkers noted a predicted protein sequence similarity between CED-3 and
3

the human and murine interlukin-1" converting enzyme. This enzyme had been
characterized as a heterodimeric cysteine protease18, and later renamed caspase-1.
Discovery of other caspases followed soon after, and necessitated the distinction of
apoptotic caspases (-2, -3, -6, -7, -8, -9, -10) versus inflammatory caspases (-1, -4, -5, 11, -12, -13, -14) (For review, see19-22).
FasL
TNF-!"

Intrinsic

Extrinsic

Mitochondrial Stress
Procaspase-8
DISC complex

Procaspase-3
Procaspase-6
Procaspase-7

Mitochondria
Cytochrome c

Active Caspase-8

Apaf-1

+ dATP

Apaf-1

Active Caspase-3
Active Caspase-6
Active Caspase-7

Apoptosome
complex
laminA

IAPs

Procaspase-9

Apoptosis

PARP
??

Cleavage of
Caspase-specific
targets

Figure 2: Differences in intrinsic versus extrinsic caspase activation
Caspase and thus apoptosis activation can occur either from extrinsic (external) or intrinsic
(internal) cellular stresses. Based on the nature of the stress, initiation different pathways are
followed. In the intrinsic pathway, mitochondrial stress causes the release of cytochrome c, which
triggers the formation of the apoptosome complex, leading to activation of the downstream
executioner caspases by caspase-9. In the extrinsic pathway, the DISC complex is activated by an
extracellular signal, which then causes the maturation of caspase-8, which cleaves executioner
caspases.

Apoptotic caspases can be classified as either initiator (-2, -8, -9) or executioner (-3, -6, 7). Like their necrotic cousins, apoptotic caspases are expressed in the cytosol as
catalytically inactive zymogens, referred to as pro-enzymes. Caspases are expressed as a
single chain polypepide that requires cleavage for maturation. Broadly described, this
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single chain is composed of three sections, the N-terminal peptide, large subunit, and
small subunit. During maturation and activation, the N-terminal peptide is cleaved off, as
is an inter-subunit linker. The length of the N-terminal peptide and inter-subunit linker
and the order of cleavage are specific to each caspase. (For review see19)
The activation of these proteolytic enzymes is cellular stress-dependent and the apoptotic
pathway which activates the caspases varies depending on the nature of the stress. In the
extrinsic pathway, an extracellular signal is received by TNF-# (tumor necrosis factor),
which is spatially associated to procaspase-8 in the DISC (death inducing signal
complex). This signal causes the recruitment of procaspase-8 to the complex and leads to
the activation of pro-caspase-8. The activation of procaspase-8 is believed to be caused
by auto-processing23 due to high local concentrations of pro-form caspase-8. Once
activated, the mature caspase-8 cleaves the downstream or executioner caspases (-3, -6, 7).
In the intrinsic pathway, mitochondrial stress induces cytochrome c release, which bind
to Apaf-1, forcing a conformational change in Apaf-1. This Apaf-1:cytochrome c
complex facilitates the formation of the apoptosome, which is a heptamer of Apaf-1 and
cytochrome c in the presence of ATP or dATP24,25. The apoptosome then recruits procaspase-9, and it is thought that the close proximity of two monomers of pro-caspase-9
induce the intersubunit cleavage activation of caspase-9. Caspase-9, like caspase-8, then
cleaves the executioner caspases thus activating them. Since the executioner caspases are
apoptosis pathway independent, their activation typically sounds the death knell for the
cell. Because of their ability to kill cells or contribute to cell survival, the ability to
control caspase function is of great utility. In this thesis, we focus on one of the
5

executioner caspases, caspase-7, exploring the molecular details of its function and
engineering a redox sensitive version of caspase-7.

L2’

Figure 3: Caspase-7 conformations
Caspase-7 is expressed as a single chain polypeptide which dimerizes and forms the procaspase-7
zymogen where loops L2, L3, and L4 are formed but are in a catalytically incompetent
conformation. Proteolytic processing cleaves the inter-subunit linker on L2 creating the mature
caspase, which is formed from two small subunits, and two large subunits. Loops L2 and L2’ from
the opposite side of the dimer are liberated during this cleavage event, but are not in catalytically
competent conformation. In the active form of caspase-7, binding a covalent inhibitor at the active
site cysteine promotes the ordering of the active site loop bundle, where L2, L2’, L3 and L4 are
clearly visible in the crystal structure. Conversely, in the allosterically inhibited form where small
molecule inhibitors DICA or FICA are bound covalently to cysteines at the dimer interface (C290),
L2’ adopts a conformation similar to the zymogen form, while L2, L3, and L4 are disordered.

Executioner caspases are obligate homodimers26,27, each composed of a large and small
subunit which are formed during cleavage activation by an upstream caspase such as
caspase-8 or -9. It is notable, however, that caspases recombinantly expressed in E. coli
self activate by an unknown mechanism. The substrate-binding groove is made up of
flexible loops on opposite sides of the two-fold symmetrical dimer. The interface of the
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homodimer of heterodimers creates a large cavity formed by the interface between the
small subunits composed of anti-parallel " strands (Figure 4). While the crystal structures
of caspase-328-34 and -635,36,27 exist, caspase-7 has more structural information available
because the three-dimensional structure of multiple conformations has been solved
previously by x-ray crystallography37-42. The notable differences between the structures
lie in the arrangement of the loops that ultimately form the substrate-binding groove. In
the inactive zymogen caspase, the intersubunit linker that is part of loop L2 is uncleaved,
lying over the cavity at the interface of the small subunits. (Figure 3) After processing,
L2 loop is split into L2 and L2’. In the crystal structure of the mature, but catalytically
incompetent form of caspase-7, loops, L2, L3, and L4 are ordered, but L2’ loops lie over
the allosteric sites and the substrate binding grooves are not competent to accept
substrate. When crystallized with a covalently bound tetrapeptide suicide substrate
(DEVD-CHO), the loops appear fully ordered39, however, the active site geometry of the
cysteine-histidine dyad is not favorable for catalysis since the catalytic thiol is covalently
modified by the bound substrate. Binding to the aldehyde containing substrate pushes the
catalytic thiol out of position for catalysis. The active-site cysteine (Cys186 in caspase-7
numbering) lies at the base of L2, and the trajectory of the distal end of L2 causes
interactions between it and L2’ from the opposite side of the dimer. Caspase-7 has also
been crystallographically observed to adopt an allosterically inhibited conformation when
small molecules DICA or FICA are bound to cysteine 29042 as represented in Figure 3. In
this structure, L2’ adopts a loop trajectory similar to that of the procaspase-7 structure or
the mature apo structure, while loops L2, L3, and L4 are disordered.
These structural data provided many insights into how the caspase works, and have
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facilitated study of the active site and the allosteric cavity42.
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Figure 4: Caspase-7 structure
Caspase-7 structure is composed of two large subunits (darker color) and two small subunits
(lighter color) forming a dimer with two fold symmetry. (A) In the active structure of caspase-7, a
DEVD substrate (spheres) is covalently bound to the active site cysteine, which lies at the base of
loop L2. Loop L2 and L2’ along with L3 and L4 arrange to form the substrate binding groove. (B)
In allosterically inhibited structure of caspase-7, L2’ from both sides of the dimer lie over the dimer
interface in a catalytically inactive form. Additionally, the loops of the active site binding groove
are disordered (dashes).

The central cavity formed between the two halves of the homodimer can be harnessed for
allosteric regulation. In the crystallographic model, allosteric inhibition can be triggered
by the introduction of a molecule covalently bound to Cys290, which restricts the
movement of Tyr223 to the up conformation. Tyrosine 223’s rotameric placement is also
critical for active site conformation stabilization through the steric interference with
Arg187. In the active form, the arginine 187’s nitrogens are within 4Å of the tyrosine
ring in the down conformation.

8

Figure 5: The caspase-7 allosteric switch
During allosteric inhibition with a small molecule bound within the cavity at the interface of the
two small subunits (allosteric cavity), tryrosine 223’s ‘up’ position (magenta) restricts arginine 187
from adopting the active conformation by forcing arginine 187 and L2 into a conformation not
amiable to substrate binding. . In the active conformation (green), arginine 187 from L2 adopts a
conformation that sterically disallows the ‘up’ conformation of tyrosine 223.

This arrangement suggests an interaction between the aromatic ring and the arginine. The
arginine needs to move toward the cavity to transition from the inactive pro form, to the
active form. This move is stabilized by the interaction, thus, the tyrosine’s placement is
critical.
In addition to R187, positioning of the L2’ loop is essential for allosteric regulation. It
should be therefore possible to emulate this inhibited conformation of L2’ down over the
allosteric cavity with a non-covalently bound small molecule, whose contact with the
cavity will be sufficient to force Tyr223 into a position unfavorable for catalysis, or to
9

block the interaction of Arg187 with Tyr223 which will block the formation of the active
site. Similarly, a variant of caspase-7 might be designed with restraints on loop
movement creating an allosterically controllable protease.

Computational Protein Redesign
The goal of the Hardy lab is to develop additional vectors of control into proteins in novel
ways using a rational design approach. By using data from x-ray crystal structures as a
starting point, computational, rational or directed evolutionary approaches can be
employed to systematically tune a protein for a desired response. Protein redesign
whether by computational, rational or directed evolution methods is not a novel idea.
Early efforts to use computers to augment structural information by way of homology
modeling started in the early 1980s43,44. Efforts to improve drug-like properties of
biological molecules have also benefited from computational design45,46. Additionally,
the use of protein engineering to stabilize complexes for crystallography and functional
studies is widely employed47,48. Computational protein design and redesign have become
very powerful tool to study not only novel folds, but also to engineer novel functions.
Efforts to computationally redesign proteins have met with mixed success49.
Computational protein design has benefited immensely from recent advances in
computing power, and thus seminal papers have been published on this topic. Early
efforts of protein design50-52 focused on a simplified problem that only targeted the
hydrophobic cores. This pioneering work was necessarily less complex, but nonetheless
established many algorithms53,54 and prompted work on large combinatorial methods that
followed55. This work emboldened protein chemists to use computational methods as the
computational results were becoming more reliable. Two general approaches have been
10

tried in this field, de novo design, and using an existing protein as a scaffold for design.
Mayo and colleagues have successfully used an automated search method to design a
novel amino acid sequence that folds similar to a zinc-finger domain in the absence of
zinc. Baker and colleagues, of Rosetta56 fame, were able to design a globular protein of a
fold that does not exist in nature in silico, and then solve the crystal structure to
demonstrate the accuracy of their approach 57. Not satisfied with strictly de novo design,
Baker and colleagues have successfully reengineered endonuclease specificity58, and built
an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction59 using similar
methods. This substantive success in the field of protein redesign illustrates the
effectiveness and more importantly, credibility of the method.
In this thesis, we examine the role of the loops of caspase-7, and their contributions to the
formation of the substrate-binding pocket. Using these data, we harness the mobility of
the L2’ loop to engineer a redox activatable caspase-7. Finally, we explore the
possibilities of allosteric cavity redesign to bind a small molecule using computational
methods, employing data and knowledge gathered from the investigations of caspase-7.

11

CHAPTER II

LOOP L2’ IS CRITICAL FOR ACTIVE SITE FORMATION
The majority of this chapter has been published: Witkowski, Witold. and Hardy, Jeanne
A. “L2’ loop is critical for caspase-7 active-site formation.” Protein Science, 2009, 18,
1459-1468.

Abstract
The active sites of caspases are composed of four mobile loops. A loop (L2) from one
half of the dimer interacts with a loop (L2$) from the other half of the dimer to bind
substrate. In an inactive form, the two L2$ loops form a cross-dimer hydrogen-bond
network over the dimer interface. Although the L2$ loop has been implicated as playing a
central role in the formation of the active-site loop bundle, its precise role in catalysis has
not been shown. A detailed understanding of the active and inactive conformations is
essential to control the caspase function. We have interrogated the contributions of the
residues in the L2$ loop to catalytic function and enzyme stability. In wild-type and all
mutants, active-site binding results in substantial stabilization of the complex. One
mutation, P214A, is significantly destabilized in the ligand-free conformation, but is as
stable as wild type when bound to substrate, indicating that caspase-7 rests in different
conformations in the absence and presence of substrate. Residues K212 and I213 in the
L2$ loop are shown to be essential for substrate-binding and thus proper catalytic function
of the caspase. In the crystal structure of the I213A mutant, the void created by side-chain
deletion is compensated for by rearrangement of tyrosine 211 to fill the void, suggesting
that the requirements of substrate-binding are sufficiently strong to induce the active
12

conformation. Thus, although the L2$ loop makes no direct contacts with substrate, it is
essential for buttressing the substrate-binding groove and is central to native catalytic
efficiency.

Introduction
Initiator caspases cleave executioner caspases in two locations to liberate an N-terminal
propeptide and cleave the intersubunit linker. Executioner procaspases are dimeric so that
cleavage of the intersubunit linker converts each half of the homodimer into one large
and one small subunit. Mature caspases then consist of four chains, with two large
subunits flanking two small subunits in the mature state. Cleavage of the intersubunit
linker results in the formation of two new termini that function as loops involved in
substrate binding. The C-terminal end of the large subunit becomes the L2 loop, whereas
the N-terminal end of the small subunit becomes the L2$ loop. The catalytic cysteine is
contained on the L2 loops, thus each half of the dimer contains one catalytic site60. The
catalytic sites are surrounded by extended substrate-binding grooves. Each substratebinding groove is composed of three loops (L2, L3, and L4) from one monomer. A fourth
loop (L2$) from the opposite monomer interacts with L2 to stabilize the substrate-binding
loop bundle in the active state (Figure 6 A,B).
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A!

B!

E196!

DEVD!

90°!

K212!

I195!
V215!
Active!

I213!
P214!

DEVD!

Figure 6: Active caspase-7
(A) The L2’ loop (colored sticks) is in the ‘‘up’’ position only when substrate binds to the active
conformation of caspase-7 (PDB ID 1F1J). Residues selected for mutation (K212, orange; I213,
magenta; P214, blue; V215, green) make interactions with the L2 loop from the opposite half of the
dimer. The two substrate-binding grooves are bound by inhibitor DEVD (light blue ball-andsticks), which is a substrate- mimicking compound. Loops L3 and L4 contribute to the substratebinding loop bundle with loops L2 and L2’. (B) Interactions between L20 (colored sticks) and L2
(gray sticks) stabilize the active form of caspase-7.

Large conformational changes in L2 and L2$ are associated with the transformation
between the caspase-7 conformational states, all of which have been structurally
characterized. When the inactive procaspase-7 zymogen39,41 is cleaved to generate mature
caspase-7,39 it remains in a conformation that has been observed crystallographically that
is between active and allosterically inhibited (“semi-active”) until substrate binds,
inducing the active caspase-7 conformation37,38,61. Caspase-7 can also be allosterically
inhibited42 by binding of effectors to a cavity at the dimer interface. In the inactive
procaspase-7 zymogen L2 and L2$ are covalently connected yet they are observed to be
pointing away from one another, separated by a stretch of disordered residues. This
conformation is very similar to that observed in the allosterically inhibited state, where
the L2$ loops interact above the allosteric site (Figure 7 C,D).
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C!

D!

V215!
P214!

K212!

I213!
Y211!

Inactive!

Figure 7: Allosterically inhibited caspase-7
(C) The L2’ loop (colored sticks) is in the ‘‘down’’ position both in the zymogen and allosterically
inhibited (allosteric model shown, PDB ID 1SHJ) conformations. The magnitude of the L20 loop
rearrangement is clearly visible compared to (A). Mutated residue Y211 is represented as yellow
while resides 212–215 are colored is as in (A). (D) The hydrogen-bonding network (dashed lines)
at the dimer interface comprises interactions between L2’ from one monomer and L2’ from the
opposite side of the dimer (dashed lines).

In the absence of substrate, the mature caspase-7 is in a partially active conformation
(Figure 8 E,F). L2 is in the conformation that allows substrate binding, but L2$ is in the
down position that is more similar to the zymogen and allosterically inhibited
conformations. Thus, the L2$ position correlates with caspase-7 activity.

E!

F!
L2 loop!
V215!

K212!

P214!
I213!

Mature!
Figure 8: Mature caspase-7
(E, F) The half-active conformation observed in the mature (cleaved but substrate-free) form of
caspase-7 (PDB ID 1K86) is colored as (A). Although the L2 loop is in a similar conformation to
the active-site-bound structure, the L2’ loops point down toward the allosteric cavity in a
conformation most similar to the allosteric/zymogen conformation. For additional clarity not
possible in paper form, see Supporting Information Movie S1.
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This canonical caspase-7 activation model suggests L2 and L2$ can only interact properly
after cleavage by initiator caspases to generate the free loops, meaning that both of the
caspase monomers must be cleaved to achieve a fully active caspase. Thus, both the L2
and L2$ loops are central in caspase activation. Recently, however, hybrid dimers of one
uncleavable and one cleavable caspase monomer suggest that cleavage of both monomers
in not necessary for formation of one catalytically active site62,63. This implies that the
uncleaved intersubunit linker can also adopt the conformation of either L2 or L2$ but not
both. The L2 loop has been implicated in an allosteric network in caspase-1 in which the
two catalytic sites are coupled through an extensive hydrogen-bond network.62 It remains
to be seen if this allosteric coupling is present in all of the caspases and what role the L2$
might play in this mechanism.
The fact that the L2$ loop is not in the correct orientation in the mature and zymogen
conformations has been suggested to be the basis for the lack of activity in the
zymogen39. Some mutagenesis inquiries have probed the role of L2 in caspase activity,
and report that mutations in this region are deleterious.64,63,32 On the basis of structural
observations, we anticipate that the L2$ loop likewise plays an important role in caspase
function. To our knowledge, we report the first systematic study of the L2$ loop. Given
the difficulties that have been encountered in developing active-site-directed caspase
therapeutics, this region is particularly interesting because it is distal from the catalytic
site, but appears to be influential for both substrate binding and catalysis.
Analysis of the existing crystallographic structures of caspase-7 indicates that residues in
the L2$ loop buttress the L2 loop into the proper configuration of the active-site loop
bundle. We investigated the role of the L2$ loop by serial alanine substitution of residues
16

211–215, which form the core of the buttress. The resulting mutants were tested to
determine the severity of these mutations on kinetics and apparent thermal stability. To
assess the structural changes in the most severely affected mutant, we solved the crystal
structure and compared the results with the existing caspase-7 structures.

Results
Role of the L2! loop in catalytic efficiency in caspase-7
The placement of L2$ in the active conformation at the base of the active-site loop bundle
suggests that it may be essential for substrate binding. Alanine mutants were designed to
probe the regions of greatest interaction between L2 and L2$ (211–215) in previous
crystal structures of caspase-7 in the active conformation (Figure 6 A).37,38,61 In caspase3, the residues in the region of the L2$ loop are identical to caspase-7 (Figure 9) with the
exception of position 211 (caspase-3 position 185). Additionally, in the crystal structures
of active caspase-3, the L2$ loop is in an identical conformation29,37,65,31,33,66 suggesting
that the buttressing role is conserved within the executioner caspases.
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Interrogated !
Region!

CASP-1
CASP-5
CASP-2
CASP-4
CASP-8
CASP-10
CASP-9
CED3
CASP-6
CASP-3
CASP-7

........LSLPTTEEFEDDAIKKAHIEK......!
........ISSQSSENLEADSVCKIHEEK......!
............SPGCEESDAGKEKLPKMRLPTS.!
........ASSQSSENLEEDAVYKTHVEK......!
............PYLEMDLSSPQTRYIPDEA....!
................EQAPTSLQDSIPAEA....!
GSNPEPDATPFQEGLRTFDQLDAISSLPTPS....!
FLRRGWDNRDGPLFNFLGCVRPQVQQVWRKKPSQA!
.......QTEKLDTNITEVDAASVYTLPAGA....!
...................DDMACHKIPVEA....!
................NDTDANPRYKIPVEA....!
213!

Figure 9: Sequence alignment of the L2’ loop in related caspases
Caspase-7 residue 213 (Ile) is conserved in size or type in not only apoptotic executioner caspases
(caspase-6, -3, and -7) but also apoptotic initiators (-8, -9, and -10), C. elegans CED3, the first
discovered caspase, the inflammatory caspases (-1 and -4) and caspase-14, the epidermal-specific
caspase. This residue is not conserved in the initiator caspase-2 or the inflammatory caspase-5.

Given the buttressing role of the L2$ loop, alanine substitution should be a useful probe
for the role of each residue in the formation of the active-site loop bundle as mutations of
critical residues would have a strong impact on Km.
Kinetics of wild-type and mutant caspase-7 variants were tested as a function of substrate
concentration to evaluate Km and kcat (Table 1).
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Km (µM)

kcat (s-1)

106 x [kcat/ Km] (M-1s-1)

Relative Activity
(relationship factor of mutant
kcat/Km versus WT )

WT

23 ± 2

0.35 ± 3!10-3

0.015

1.0

Y211A

18 ± 10

0.39 ± 3!10-3

0.021

1.4

K212A

210 ± 20

0.93 ± 4!10-2

0.004

0.26

I213A

480 ± 50

0.07 ± 5!10-3

1.5!10-4

0.01

P214A

8±1

0.10 ± 4!10-3

0.012

0.8

Y215A

26 ± 8

0.70 ± 2!10-2

0.026

1.7

!
Table 1: Kinetic parameters for caspase-7 alanine-substitution mutants
Michaelis-Menten kinetic parameters measured on L2’ alanine-substitution mutants demonstrate
that positions K212 and I213 are most affected by the alanine substitution.

As anticipated, mutation of two of the residues, K212 and I213, had a significant effect
on substrate binding as assessed by Km, while the Km for K212A was ∼10-fold weaker
than wild-type caspase-7. The Km for I213A at ∼20-fold weaker than wild type is the most
significant effect observed. I213A is the only mutation that has a significant impact, an
∼5-fold decrease, in kcat. Mutation at Y211, P214, and Y215 had minimal impact on the
catalytic efficiency. Catalytic efficiency (kcat/Km) of only K212A and I213A was
significantly different from wild type, at 4- and 100-fold decreases, respectively. These
results identify K212 and I213 as the most critical residues in the L2$ buttress.
Alignment of the L2$ region of the caspases (Figure 9) indicates hydrophobic and size
conservation of the 213 position, but not a strict conservation of amino acid identity.
Caspase-1, -3, -7, and -10 use isoleucine at this position, whereas other caspases
substitute only valine and leucine, which are nearly isosteric with isoleucine. Position
212, which exhibited the second most significant Km effect when mutated to alanine, is
not conserved across the caspase family. Position 212 is nearly always hydrophilic;
19

however, sizes vary from small (serine) to long (lysine) or bulky (histidine and tyrosine).
In the active conformation of wild-type caspase-7, the exposed aliphatic portion of the
lysine side chain is packed against the aliphatic portion of E196 (Figure 6 B).
Interestingly, these residues are not strictly conserved in the third executioner caspase,
caspase-6. Conservation of this region is weak compared with the region flanking the
catalytic cysteine C186 (residues 178–188).
L2! mutations affect protein stability
Alanine mutations have been reported to generate cavities in protein cores67. Because
alanine mutants have the possibility of introducing a destabilizing cavity, we probed the
stability of the protein in the mature (substrate unbound) form using thermal denaturation
monitored by circular dichroism (Figure 11). Inspection of caspase-7 structures suggests
that the only important interactions that form in the substrate-bound conformation but not
in the mature or zymogen form are between L2 from one monomer and L2$ from the
opposite monomer. Thus, interrogation of the stability of wild-type and mutant caspases
in the active conformation [with substrate-like inhibitor, the caspase-binding peptide
aspartate–glutamate–valine–aspartate (DEVD) bound] was also relevant.
The serial alanine mutations appear to have no discernable effect on the overall fold of
the protein in either the inhibitor-bound versus unbound states, as the measured spectra at
25°C were unaffected by mutation. The melting temperature (Tm) of all mutants in the
unbound form was similar to wild type at ∼60°C, except for the P214A mutation which
had a Tm of 46°C (Figure 11).
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Figure 10: Tm Curve Data for WT and alanine scanning mutants

Melting Temperature (°C)

Raw circular dichroism data monitored at 222 nm during a thermal denaturation of proteins. Tm
calculated by fitting a Boltzmann sigmoidal curve to data collected. Data for V215A,
K212A+DEVD-CHO and WT+DEVD-CHO were collected in triplicate, not shown. All other data
were duplicate measurements made independently on different preparations on separate days.

Figure 11: Melting temperatures and cavities generated in caspase-7 variants.
Melting temperatures (Tm) were measured by thermal denaturation monitoring the change in CD
signal at 222 nm in the presence (white bars) and absence (black bars) of the active-site inhibitor
peptide DEVD-CHO. Measurements were made at least in duplicate with independently prepared
samples on separate days. Error bars represent standard deviation between replicates measured on
separate protein samples on different days.

We had hoped to also measure thermodynamic stabilities of the caspase-7 mutants;
unfortunately, unfolding of wild type and all of the mutant caspase-7 variants was
irreversible and precluded accurate assessment of %Gunfolding. We calculated the predicted
volume changes each mutation could contribute to the overall structure (Figure 12) of
caspase-7 in the active conformation assuming there were no other structural changes in
the protein, either backbone or side chain position. From these figures, we were able to
assess the potential volume of each deletion and what role it might play in the stability of
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each protein. The Matthews group has systematically assessed the effect of cavityforming mutations in the core of T4 lysozyme. In one study of 44 large amino acid to
alanine substitutions, cavities between 17 and 123 Å3 were observed
crystallographically.67 These cavities correlated with decreases in stability (%%G) of 0.9–
5.0 kcal/mol. Several cavities were observed in the range of 25 Å3 that had %%G ranging
from &3.2 to &2.7 kcal/mol. In T4 lysozyme, a 1.9 kcal/mol change in %%G corresponds
to approximately a 5° decrease in Tm.68 Thus, the 14° decrease in Tm of unbound P214A
could reflect a %%G of greater than 4 kcal/mol.
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Figure 12: Predicted volumes of cavities in models of mutant proteins
Volumes of cavities in models of mutant proteins generated computationally in PyMol were
assessed with Pocketfinder. The deleted volumes are shown as colored pillows to illustrate the
chemical environment and residues forming the generated cavity. Change in the Tm of caspase- 7
dimers in the presence of active-site-binding peptides (DEVD-CHO) relative to ligand free is also
listed.

Interestingly, the Tm difference between mature and active-site-bound forms was
pronounced, with an average 18.7°C increase in Tm of the active-site-bound form over the
unbound form. The single observed structural difference between these two forms is that
the inactive, unbound form is able to sample both the up conformation of L2$ and the
inactive down conformation of L2$. When substrate is bound, L2$ is locked in the active

26

up conformation. Thus, when the protein adopts the up, bound form, it appears to be
significantly stabilized by the interactions between L2$ and L2 from opposite monomers
and by interactions with substrate.
I213A has a smaller than average %Tm of 7°C between the forms (Figure 11), indicating
that an energetic penalty must be paid to adopt this conformation because the active form
is less stable to thermal denaturation. The dramatically destabilized P214A mutant, on the
other hand, showed a %Tm of 31°C between bound and unbound forms. Although the
identity of 214 seems to be more influential in the inactive form, in the active form, the
stability is comparable to the wild-type enzyme. This can be explained by structural
examination of the active form where P214 seems to have a more limited role in
buttressing than I213 (Figure 6, Figure 7, Figure 8). In the active conformation, L2–L2$
physical interactions tend to dominate over any geometric constraints imposed by P214.
The substitution of P214A has a negligible effect on active (bound) enzyme stability;
however, in the inactive form, the hydrogen-bonding network present between L2$ and
L2$ from the opposite monomer would likely be disrupted as the geometric constraints
imposed by the proline at position 214 are removed by the alanine substitution. This
substitution, however, does not inhibit dimerization of the protein, as measured by size
exclusion chromatography (Figure 13). Both WT and P214A proteins ran at an
apparently smaller size than expected for the dimer of caspase-7 (60 kD). We noted a
decrease in apparent size of P214A relative to WT, however we postulate that the more
flexible nature of the loops decreases the proteins apparent interaction with the gel,
causing the smaller than expected (60 kD) size.
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RT
(mL)

SEC
Observed
MW (KDa)

Expected
MW (KDa)

P214A

15.68

45

60

P214A +
DEVD

15.26

55

61

WT

15.28

54

60

WT +
DEVD

15.33

53

61

Protein

Standards

Figure 13: Size exclusion chromatography
Size exclusion chromatography of caspase-7 WT and P214A with and without inhibitor bound. In
the presence of inhibitor, P214A’s calculated size is similar to WT with inhibitor. The difference in
size of apo P214A versus WT is not appreciable.

Analysis of caspase-7 by analytical ultracentrifugation
We postulated that the decreased stability of caspase-7 P214A due to the more flexible
L2’ loop would have an appreciable effect the dimerization constant. Clark and
colleagues have reported an estimation of the dimerization constant for caspase-3 to be
below 50 nM69, so we imagined that caspase-7 P214A would be sufficiently destabilized
in the apo state to monitor this by analytical ultracentrifugation. P214A in the absence of
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covalent catalytic inhibitor was studied by analytical ultracentrifugation in equilibrium
mode to determine dimerization constant. The estimated molecular weight from AUC
was determined to be 53 kD and a single species. Fitting monomer-dimer equilibrium
was unsuccessful as at experimental conditions of 10-20 µM, no monomer was detected.
These data suggest that the Kd of dimerization is significantly below 10 µM and does not
appear to be changed from WT caspase-7. Thus, further experiments to determine
experimental Kd of WT by AUC was not attempted due to equipment restraints. In
hindsight, the ability to collect accurate kinetics on protein at 100 nM should have
suggested that the P214A’s dimerization constant was below 100 nM.

Figure 14: Equilibrium AUC analysis of P214A apo
Single species fitting of equilibrium data based on two concentrations and three rotor speeds. Fitted
line (blue dots) overlays data (black dots) very well, with statistical residuals (bottom) maintaining
sufficient randomness.

Additional experiments undertaken to lower experimental concentrations and thereby
increase monomer population in solution were unsuccessful, because the limit of
detection of the instrument was reached. At concentrations below 5 µM protein, data
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collected were too noisy to process, making measurements in the concentration regime of
caspase dimerization impossible69. Thus we can only conclude that the dissociation
constant is well below 10 µM. Furthermore, because caspase-7 and the P214A mutant
show activity at 100 nM protein concentrations, and dimerization is known to be essential
for activity, we can further conclude the dissociation constant is less than 100 nM in the
presence of substrate.

Figure 15: MW calculation for P214A apo AUC data
Fitting parameters and results from single species fitting of equilibrium data based on two
concentrations and three rotor speeds. A molecular weight of 53kD was fit with 2084 points, with
an RMSD from fit of 0.011.

Thus, we can conclude that substrate binding and the concomitant stabilization of
interactions observed between the L2 and L2$ loops are the most critical factors in
significant stabilization of the active-bound conformation. Indeed, substrate binding
appears to be so influential in locking L2$ securely into the up conformation that it can
overcome significant thermodynamic destabilization in the unbound state. Because
P214A had negligible effect on both the stability of the substrate bound form and the
kinetics of the enzyme, we focused our investigation on the structural differences caused
by the I213A mutation to further understand the structural role of the L2$ loop in
substrate binding and catalysis.
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P214A Mutation does not affect DICA binding
In the crystal structure of caspase-7 bound to allosteric inhibitors (1SHJ and 1SHL), loop
L2’ is positioned over the allosteric site. In those structures, residues I213 and Y211 form
a hydrogen bonding network that potentially stabilizes the resting state or ‘half active’
conformation of caspase-7. Stability measurements (Figure 11) suggest that in this
hydrogen bonding network is disrupted by the mutation of P214 to alanine, likely due to
the additional degrees of freedom afforded by the alanine. Proline imposes geometric
restraints not found in alanine, and the subsequent destabilization of the loops could
account for the 13.8° difference in Tm. To investigate whether this difference and loop
flexibility would affect DICA binding and removal, caspase-7 WT and P214A were both
incubated with DICA. Both proteins responded similarly to DICA inhibition, and were
found to be fully inhibited within 1 hour. Reductive removal of DICA from the allosteric
cavity using DTT at various concentrations (100 µM and below in a two fold dilution
series) indicated no statistically significant difference between the wild type enzyme and
the P214A variant. (Figure 16) This suggests the loop L2’ makes additional interactions
with DICA that stabilize L2’ in the down conformation, occluding the accessibility of
reductant to C290 in both WT and P214A. Interestingly, it was found that high
concentrations of TCEP have an inhibitory effect on both WT and P214A caspase-7 at
concentrations above 50 µM. This same effect was not observed with the use of DTT.
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Figure 16: Percent recovery of activity as a function of DTT concentration
Caspase-7 WT and P214A do not show statistically significant differences when inhibited with
allosteric disulfide linked DICA, followed by treatment with DTT reductant. Activity returns as a
function of reductant concentrations to both WT and P214A.

Crystallographic studies of I213A in the presence of active-site inhibitor
Crystals of caspase-7 I213A with DEVD covalently bound in the active site to lock the
protein in to the active conformation were grown in a variation on known conditions,61
and the structure was solved at 2.6 Å (Table 2). To avoid model bias during structure
determination, we omitted all of the active-site loops from the molecular replacement
search model and thus calculated an omit map that is unbiased in the loop region as our
initial map (Figure 17 A,B). Compared to an active caspase-7 structure that crystallized
in the same form (1F1J37), the RMSD of all atoms was found to be 0.191 Å, further
supporting the observation that the I213A mutation had no effect on the overall fold of
the protein. The substrate-binding grooves and active-site inhibitor conformations in our
structure were virtually unchanged from wild-type caspase-7.
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Diffraction Data
Wavelength (Å)
Resolution Range (Å)
Measured reflections
Unique reflections
Completeness (%)
Redundancy
<I/!I>
Space Group
a = b (Å)
c (Å)
# = " (°)
' (°)
Rsym

1.54
50-2.61 (2.70-2.61)
26499
10599
97.8 (92.0)
2.5 (2.5)
22.5 (1.99)
P3221
89.4
186.1
90
120
8.3 (69.4)

Refinement Statistics
Atoms
Water molecules
Rwork (%)
Rfree (%)
RMSD bond length (Å)
RMSD bond angle (°)
Average B-factor (Å)

3919
119
19.9
25.1
0.019
1.876
51.82

Table 2: Statistics for the x-ray crystal structure of caspase-7 I213A
Data in parenthesis are for the highest resolution bin

The greatest difference between the wild-type and the I213A structure was in the Y211
region (Figure 17 A–C). Y211 is unresolved in most caspase-7 structures of the active
form, and only recently has been observed in structures (PDB ID 2QLF and 2QLJ) of
active caspase-7 bound to peptide inhibitors with aldehyde warheads61.
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L2!
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L2ʼ

B!
G274!

Y211!
F273!

A270!

C!

90°!

D!

Y211!

Y211!

Y211!

K212!

K212!
R271!

R271!

I213!

E!

F!

K212!

Y211!
K212!

K286!
Y211!
G176!

K286!

R271!

Y211!
G176!

R271!
I213!

Figure 17: Crystallographic evidence of compensatory mechanism that facilitates
active-site-binding in caspase-7 I213A.
(A) Caspase-7 I213A structure with buttress region highlighted in inset. (B) 2Fo-Fc density (blue
mesh) from the initial omit map (residues 211–215 omitted from the phase calculation) and final
refined model of I213A (yellow sticks) shown in same orientation as (A). (C) is as (B) but rotated
90° for clarity. The unbiased omit map clearly indicates the down position for Y211. (D) Wild-type
caspase-7 (green sticks) is superimposed with the final I213A model, demonstrating that the
conformation of Y211 fills a structural void when the I213 side-chain is deleted. (E) The
environment (gray spheres) into which Y211 (yellow spheres) inserts is hydrophilic in nature to
accommodate the hydoxyl moiety. (F) Residues forming the cavity into which Y211 insert are in a
nearly identical conformation in wild-type caspase-7 (green sticks) and I213A (yellow sticks).
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In both these structures, Y211 is solvent exposed (Figure 17 D,F). In our structure
(yellow), Y211 exhibits a radically different conformation, burying itself into a newly
formed surface cavity. This burial appears to be a compensatory mechanism for the
I213A cavity-forming mutation (Figure 17 D,E). This position of the tyrosine fills a void
in the region, where I213 is found in the wild-type structure. In the wild-type
conformation, Y211 burial is sterically occluded by I213 (Figure 17 E).
This structural observation helps to explain the diminished kcat, in the context of residual
catalytic activity in the I213A mutant. Given that the apparent thermal stability of I213A
in the active-site-bound form is lower than any of the other mutants, and the lack of any
other structural changes in this mutant crystal structure, we can conclude that the cavity
formed by deletion of the I213 side-chain is so unfavorable as to prevent proper
formation of the loop bundle without some compensatory reorganization. The
compensatory conformation we observe allows the formation of a catalytically competent
enzyme but not without an energetic penalty.

Discussion
Based on the work presented here, two main points emerge. First, binding of substrate
stabilizes caspase-7 via a structurally validated mechanism. Second, the core of the L2$
loop is residue I213 and this buttressing region is an essential component of active
caspase-7. If the core of the L2$ loop is perturbed, then the L2$ loop does not properly
hold L2 in place, the substrate-binding loop bundle is therefore destabilized and Km of the
resulting mutants are increased.
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Caspase-7 is a constitutive dimer and is not believed to exist in the monomeric state to a
significant degree70. In contrast, the initiator caspase-9 is predominantly an inactive
monomer before activation by the apoptosome. Binding of active-site inhibitors drives
caspase-9 to the dimeric state70. Thus, it is plausible that other caspases would likewise
be stabilized by binding of active-site inhibitors. To our knowledge, no other group has
shown and quantified the dramatic stabilization of the active-site bound form of caspase7 compared with the unliganded state. Prior computational analysis of the stability of the
active versus unbound conformation mirrors our experimental results, indicating that the
L2$ up or active conformation of caspase-7 was significantly more stable than the L2$
down conformation71.
The roles of individual residues in the L2$ loop obviously change depending on the state
(active-site-bound or unbound) of the protein. The structures of the mature unbound form
of caspase-7 (Figure 8 E,F) when compared with the active (Figure 6 A,B) and
allosterically inhibited (Figure 7 C,D) forms suggest an ensemble of states that are in
dynamic equilibrium with one another. Two of our mutants, I213A and P214A, support
the idea that the L2$ loop is critical for stabilizing the active-site-bound conformation.
I213A caspase-7 has the same apparent thermal stability in the unbound form as does
wild type. This indicates that the equilibrium constant for unfolding of the unbound form
is likewise unchanged from wild type. On the other hand, the Tm of the active-site-bound
form is slightly lowered, possibly suggesting that an energetic penalty must be paid to
achieve this conformation. The crystal structure of I213A indicates that the decrease in
stability is due to the cost of hydrophilic burial when Y211 intercalates into the I213A
cavity to properly buttress the loop bundle (video of interaction can be accessed from
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Protein Science Supplementary resource website, at:
http://onlinelibrary.wiley.com/store/10.1002/pro.151/asset/supinfo/PRO_15_sm_suppmo
v2.mov?v=1&s=479f68a02900b7636d650589416d8e9a5bcb35ea). We anticipate that in
the unbound form of I213A, L2$ is free to sample the down conformation, whereas in our
structure, binding at the active site locks L2$ into the active, up, conformation. If caspase7 natively sampled the active, up, conformation to a significant degree when the active
site was empty, this up conformation would lower the stability of the unbound form of
the enzyme. Because the I213A unbound apparent thermal stability is unchanged, it
seems that the up conformation of the L2$ loop does not contribute significantly to the
conformational equilibrium ensemble of the unbound form. Thus, proper ordering of the
L2$ loop as a buttress for L2 is so essential for active-site-binding that the enzyme will
pay an energetic penalty to maintain the active state.
The P214A mutant displays the opposite effect on stability. P214A is destabilized in the
unbound state by a significant margin (14°C relative to wild type). Interestingly, when it
is locked into the active conformation by active-site binding, the complex is as stable as
the wild-type enzyme. This indicates the absence of energetic penalties like those
observed for I213A and further suggests that the conformation of this mutant when the
active site is bound is identical to wild type. The interactions of L2 with L2$ are the only
additional interactions within the caspase protein itself that are observed on going from
mature unbound caspase-7 to active-site-bound caspase-7. The fact that a dramatic
destabilization of the unbound form of P214A can be overcome by active-site binding
indicates that these L2/L2’ interactions are responsible for the jump in apparent thermal
stability observed in all versions of caspase-7. Structural analysis suggests that the L2$-
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loop up conformation should be more stable as it has better burial of exposed
hydrophobic residues. Likely, an entropic penalty for ordering of mobile loops prevents
this conformation in the absence of active-site binding. Moreover, the conformational
equilibrium in the bound state has essentially no component of the unbound state, which
would lead to destabilization of both the unliganded and liganded states.
One of the looming controversies in understanding caspase structure and activity is the
structural state of the mature (cleaved) protein in the absence of active-site ligand. There
is but one existing crystal structure of unliganded, mature caspase-739. In this structure,
the active-site loops do not adopt the substrate-bound conformation (L2 and L2$ up), but
are in a half-active conformation with L2 up but L2$ down. In contrast, mature caspase-3
has been reported to exist in the liganded conformation (L2 and L2$ up) with an empty
active site, crystallized in the presence of what the authors term a noncatalytic site
inhibitor, which is not observed in the crystal structure.31 The fact that a mutation in L2$
exists, namely P214A, that dramatically affects the stability of the unliganded state but
not the liganded state suggests that without ligand, the L2$ loop is in a conformation that
differs from the active state. If the unliganded enzyme “rested” in the active (L2$ up)
conformation, as suggested by the mature caspase-3 structure31, then this mutation should
have the same energetic effect on the active-site liganded form as on the unbound form.
As this is not the case, our analysis supports the notion that structural rearrangements that
are observed in the existing crystal structures of caspase-737,39,41,42,61 are the biologically
relevant conformations.
In the context of the other mutagenesis data, the Y211A mutation indicates that
interactions between the backbones of the L2$ loops covering the allosteric pocket are the
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major energetic contributors to the allosterically inhibited/zymogen complex. In the
active conformation, the interactions between the L2 loop from one half of the dimer and
the L2$ loop from the other half of the dimer have a tremendous stabilizing effect on
caspase-7, as the addition of active-site inhibitor increases the apparent thermal stability
of the complex by 12–19°C. Thus, the L2$ loop appears to play important roles in both
substrate binding and maintaining caspase-7 in an inactive yet still dimeric conformation.
We report a large perturbation (10- to 20-fold) in the Km of two caspase-7 variants
(K212A, I213A) with alanine substitutions in the L2$ loop. Although the L2$ loop is
further away in both amino acid sequence and in space than the L2 loop is from the
catalytic residues, our reported mutations had as a great an effect on substrate binding
and catalytic efficiency as did mutations in the L2 loop. Clark and coworkers32 mutated
caspases-3 residues 167, 169, 173, and 203 (homologous residues in caspase-7 are 190,
192, 196, and 229) to alanine. The residue with the most significantly impaired substratebinding properties was D169A, in which Km was increased 35-fold relative to wild type.
It is significant that our mutants had the same magnitude effect on substrate binding as
mutations in the L2 loop because structurally the two loops also appear to act in concert.
Another region of the caspase substrate-binding loop bundle that has been widely
discussed as being critical for caspase activity is the DDD “safety catch” in the L2$ loop
in caspase-3. This “safety catch” comprises residues 179–181 (caspase-7 residues 205–
207) and was found to be critical for activation of procaspase-364. The DDD “safety
catch” region is further from the active site, has not been observed in crystal structures,
and is unlikely to make physical buttressing interactions like those we observe in the L2$
buttressing region. Although the DDD region is essential for proper cleavage and
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activation of caspase-3, the L2$ loop may be a more tractable target for new methods of
caspase regulation.
Before this work, the L2$ loop was implicated in both the active and
zymogen/allosterically inhibited conformations. In the active state, L2$ is part of the
substrate-binding loop bundle. In the zymogen/allosterically inhibited state, L2$ forms a
lid occluding the allosteric cavity. Interconversion between the active and inactive
conformations had been observed, but the energetic contributions of L2$ to these two
conformations were unclear. Our work demonstrates that residues 212 and 213 are
critical for proper functioning of the L2$ loop, particularly in binding substrate. We have
shown that I213, in particular, serves as a critical buttress for holding the L2 loop (which
is connected to the catalytic cysteine) in place and thus stabilizing the active form of the
enzyme. If L2$ is not in the up conformation, the entire loop bundle is destabilized. This
buttressing region is present in the homologous conformation in structures of the other
active caspases indicating that the results we report may be relevant to the entire caspase
family.
This understanding of the role of the L2$ loop as critical for formation of the active-site
loop bundle also provides clues toward new mechanisms for pharmacological control of
caspases. Molecules that bind overlapping with the buttressing region occupied by I213
and neighbors should work as allosteric inhibitors of caspase function. Similarly,
molecules that bind behind the L2/L2$ interacting region [which is on the back side of
caspase-7 in (Figure 6 (A), Figure 7 (C), Figure 8 (E)] should stabilize the active
conformation and serve as heterologous caspase activators, which are a long-sought
entity. Given recent evidence that the uncleaved form of caspase-7 can support catalysis
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in a hemicleaved heterodimer,62,63 this mechanism of activation might even prove more
relevant for activation of procaspases.

Materials and Methods
Caspase-7 mutant generation, expression, and purification
Wild-type and mutant versions of caspase-7 were expressed from a two plasmid
expression system39. The constructs encoding residues 50–198 comprise the large
subunits and were contained in the pRSET(AmpR) plasmid. The constructs encoding
residues 199–303 and one codon for Q plus a six-histidine tag are contained in the
plasmid pBB75 (KanR) plasmid72. Mutants in the small subunit were generated using
QuikChange (Stratagene) site-directed mutagenesis. The recombinant large and small
subunits were coexpressed in E. coli in 2( YT media grown for 18 h after induction with
1 mM Isopropyl "-d-1-thiogalactopyranoside at an OD600 of 0.6. Wild-type and mutant
caspase-7 variants were purified using Ni-affinity liquid chromatography (HiTrap
Chelating HP, GE). After binding of protein to the affinity column, the protein was eluted
with a step gradient from 50 to 250 mM imidazole. Protein was diluted to 50 mM NaCl
and then purified using a Macro-Prep High Q ion exchange column (Bio-Scale Mini 5
mL, Bio-Rad) with a linear gradient from 50 to 500 mM NaCl in 20 mM Tris buffer pH
8.0, with 2 mM DTT. Protein eluted in 120 mM NaCl and 20 mM Tris pH 8.0 was
assessed for purity by SDS-PAGE to be 98%+ pure and stored in elution buffer at &80°C.
Caspase-7 I213A crystallization and X-ray data collection
To prepare I213A crystals, 29 µM I213A protein in a buffer containing 120 mM NaCl
and 20 mM Tris pH 8.0 was incubated at room temperature with a 3:1 molar ratio of
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DEVD-CHO (asp–glu–val–glu-aldehyde, BioMol) to protein for 3 h. Optimal protein
labeling occurred with the addition of enzyme to the small volume of DMSO-solvated
inhibitor. The extent of enzyme labeling was confirmed by activity determination. Protein
was then concentrated using Millipore Ultrafree 5K NMWL membrane concentrators
(Millipore) to 11 mg/mL as assessed by absorbance at 280 nm. Crystal tray setup was
conducted on ice with cooled buffers. Crystals were grown in 2 µL hanging drops with
mother liquor consisting of 14% polyethylene glycol 3350, 300 mM diammonium
hydrogen citrate at pH 5.6, 10 mM guanidine hydrochloride, and 10 mM DTT in a 1:1
ratio of protein mother liquor. Crystals grew to a maximum of 200 µm in 48 h at 4°C.
Crystals were cryoprotected in 14% polyethylene glycol 3350, 300 mM diammonium
hydrogen citrate at pH 5.6, 21% glycerol, and 10 mM DTT with a 60 second incubation,
then frozen by rapid immersion in liquid N2. Data were collected on an R-axis IV++
detector using a Rigaku X-ray generator and showed diffraction data to 2.4 Å. Indexing,
integration, and scaling were carried out on HKL200073. Low I/) in the high-resolution
shells forced the dataset to be restricted to 2.61Å. Only 47° of data were collected,
resulting in low overall data redundancy, because of a power outage leading to the loss of
the crystal.
Structural determination
Phase information was obtained by molecular replacement using 1F1J as the search
model with residues 194–196/494–496 and 212–213/512–513 omitted during searches
with CCP4 AMoRe74. Tyrosine at position 211/511 was not present in the parent model.
Removed residues were rebuilt into unambiguous density using O,75 then refined with
three rounds of Refmac restrained refinement using medium strength NCS averaging
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restraints. Waters were inserted with multiple rounds of ARP/Warp then checked for
stereochemical viability manually. The final refined model contains residues 58–196,
211–303 for chain A and 57–196, 211–304 for chain B. The inhibitor is modeled as
chains C and D, with residue numbers 701–705 and 801–805, respectively, and 119
ordered waters as chain W.
Caspase activity assays
Enzyme concentrations were determined by active site titration with suicide substrate
DEVD-Fluoromethylketone (BioMol) in caspase activity buffer containing 100 mM
Hepes pH 7.0, 10% polyethylene glycol 400, 0.1% CHAPS (3-[(3cholamidopropyl)dimethylammonio]-1-propanesulfonate), 5 mM "-mercaptoethanol, and
5 mM CaCl2 against flourogenic substrate, DEVD-AMC (7-Amino-4-methylcoumarin),
Ex365/Em495 (BioMol). Active site titration setups were incubated over a period of 4 h
in 120 mM NaCl, 20 mM Tris pH 8.0 at nanomolar concentrations. Optimal labeling was
observed when protein was added to DEVD-FMK solvated in DMSO in 96-well Vbottom plates, sealed with tape, and incubated at room temperature. Ninety microliters of
aliquots were transferred to black-well plates in duplicate and assayed with 50-fold molar
excess of substrate. For kinetic measurements, 50 nM protein (500 nM in the case of
K212A, I213A) was assayed over 0–180 µM DEVD-AMC (0–500 µM for K212A,
I213A) over a course of 7 min. Assays were performed at 37°C in 100 µL volumes in
microplate format using a Molecular Devices Spectramax M5 spectrophotometer. Initial
velocities versus substrate concentration were fit to a rectangular hyperbola using GraFit
software (Erithacus Software) to determine kinetic parameters Kmand kcat.
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DICA inhibition and reduction assays
DICA removal assays were conducted on both WT and P214A proteins buffer exchanged
into 10mM sodium phosphate buffer pH 7.5. Proteins were then incubated for 1h in 10X
molar excess of DICA, followed by a buffer exchange to remove excess DICA. Proteins
were then diluted to 110 nM as assayed by A280, and incubated in a 2 fold dilution series
of DTT (starting at 100 µM) for 30 minutes and assayed for activity against a control
under identical conditions without DICA.
Sizing column analysis
The oligomeric state of the caspase-7 WT and P214A in the presence and absence of
DEVD-CHO was determined by running protein samples on a Superdex 200 10/300 GL
(GE Healthcare) gel-filtration column. Both inhibited and apo proteins were then buffer
exchanged into 20mM Tris, pH 8.0, 100mM NaCl using Millipore Ultrafree 5K NMWL
membrane concentrators (Millipore), and 200 µl of protein (1.2 – 2 mg/ml) was loaded
onto the column. Protein was eluted with 20mM Tris, pH 8.0, 100mM NaCl. The identity
of the peak fractions and the loaded protein sample were analyzed by SDS-PAGE. Four
different molecular weight standards (Albumin, Chymotrypsinogen A, Ribonuclease A,
Ovalbumin) from the gel-filtration calibration kit (GE Healthcare) were run in the same
conditions and a standard plot was generated to calculate molecular weights of caspase-7
WT and P214A in presence and absence of inhibitor.
Analytical ultracentrifugation
Analytical ultracentrifugation of caspase-7 P214A in equilibrium experimental mode
were run on Beckman Optima XL-1 analytical ultracentrifuge using an An-60 Ti rotor
with a 6 cell equilibrium cuvette (Spin Analytical). Proteins were buffer exchanged into
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10mM sodium phosphate buffer pH 7.5 and concentrated using Millipore Ultrafree 5K
NMWL membrane concentrators (Millipore). Protein concentrations of 15 µM, 10 µM
and 1 µM were run to equilibrium at 14,000, 18,000 and 21,000 RPM for 14 hours each
at 20°C and monitored by UV at 280 nM in columns heights of ~2.8mm. Density of the
buffer and the specific volume of the protein were calculated with ULTRASCAN II76,
while data for the 15 µM and 10 µM were analyzed by SEDFIT77 and SEDPHAT77,78
using the continuous distribution model. Additional analytical ultracentrifugation data
analysis support was graciously supplied by Dr. Jeffery Lary of the University of
Connecticut.
Thermal stability determination
Thermal denaturation of wild-type or caspase-7 variants was monitored by loss of
circular dichroism signal at 222 nm on a J-715 circular dichroism spectrometer (Jasco)
with a PTC-348WI Peltier controller. Inhibited protein was prepared by 4-h incubation
with 3M equivalents of DEVD-CHO (asp–glu–val–glu-aldehyde, BioMol) at a
concentration of 6–12 µM in 120 mM NaCl, 20 mM Tris pH 8.0. Both inhibited and apo
proteins were then buffer exchanged into 10 mM phosphate buffer, pH 7.4 using
Millipore Ultrafree 5K NMWL membrane concentrators (Millipore) for repeated
concentration and dilution until NaCl concentration was below 1 nM and protein
concentration of ∼12 µM as assessed by absorbance at 280 nm. Data were collected in
duplicate on separate days and fit using Origin Software (OriginLab) using sigmoid fit.
Assessment of generated cavity volumes
Models of the alanine-mutant caspase-7 variants were generated in PyMol79 and analyzed
with Pocketfinder80 to predict the volume of pockets created by alanine mutations.
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CHAPTER III

A DESIGNED REDOX-CONTROLLED CASPASE
Abstract
Caspases are a powerful class of cysteine proteases. Introduction of activated caspases in
healthy or cancerous cells results in induction of apoptotic cell death. We have designed
and characterized a version of caspase-7 that can be inactivated under oxidizing
conditions like those found extracellularly, then reactivated under reducing, intracellular
conditions. This version of caspase-7 is allosterically inactivated when two of the
substrate-binding loops are locked together via an engineered disulfide. When this
disulfide is reduced, the protein regains full function. The inactive loop-locked version of
caspase-7 can be readily observed by immunoblotting and by mass spectrometry. The
reduced and reactivated form of the enzyme observed crystallographically is the first
caspase-7 structure in which the substrate-binding groove is properly ordered even in the
absence of an active-site ligand. In the reactivated structure, the catalytic dyad cysteinehistidine are positioned 3.5 Å apart in an orientation that is capable of supporting
catalysis. This redox-controlled version of caspase-7 is particularly well-suited for
targeted cell death in concert with redox-triggered delivery vehicles.

Introduction
The loops that form the caspase substrate-binding groove are extraordinarily mobile and
controlling their conformation controls caspase function. Amongst caspases, the most
thorough molecular descriptions of activation, regulation and inhibition have been in
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caspase-7. In the procaspase-7 zymogen, the active-site loops are disordered and
incompatible with substrate binding39. Upon activation the active-site loops are partially
ordered, but the L2’ loop remains in an inactive, down conformation (Figure 18 A). From
this state caspase-7 is competent to bind substrate or to bind allosteric inhibitors,
mutually exclusively. When substrate binds, L2’ moves to an up conformation, forming a
foundation or buttress beneath the L2 loops37,39,41,61. When caspase-7 binds allosteric
inhibitors in a cavity at the dimer interface, the L2’ loops are held in the down
conformation and the enzyme is inactive81,82. Thus controlling caspase-7 loop
conformations is an effective way to modulate activity.
Caspases are found only intracellularly and must function inside the cell to activate
apoptosis. Caspases make use of a cysteine-histidine active-site dyad for proteolysis. The
catalytic cysteine nucleophile must be maintained in a reduced state to function.
Glutathione is the most prevalent cellular redox component. Intracellular glutathione
concentrations in healthy cells range from 1-5 mM, with cancerous cells showing
concentrations up to 7-fold higher,83 whereas extracellular concentrations are 1-4 µM84.
Thus differences in redox environment provide an intriguing means of differentially
controlling intracellular and extracellular activity.
Caspases are exquisitely useful cellular players. Once activated they singlehandedly
induce the demise of a cell. There is a great deal of interest in small-molecule activation
of caspases, however this has been challenging to achieve85-87. Another option for
selective killing of cells therapeutically is the use of pre-activated caspases. Injecting
activated caspases, or any activated protease, into circulation is likely to produce many
unwanted and deleterious effects. In order to avoid these complications while still taking
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advantage of the cell-killing properties of activated caspases, we aim to engineer a
version of the executioner caspase-7 that can be held in an inactive conformation in the
oxidizing extracellular environment, but regains full activity in reducing intracellular
conditions. Targeted delivery of this type of engineered caspase could potentially provide
a safe and effective mechanism of selectively killing unwanted cell types.

Results
Rational design of a redox activatable caspase-7.
The aim of this work is to control the conformation of the L2’ loops in order to
allosterically regulate caspase-7 function. In the crystal structure of caspase-7 bound to
allosteric inhibitors FICA or DICA, caspase-7 attains a conformation that is distinct from
the mature or substrate-bound forms. We have previously shown that caspase-7 likewise
exists in two distinct conformations in solution88, a bound active state and an unbound
inactive state. In the inactive state with no substrate present, the L2’ loops rest over the
allosteric cavity and do not contribute to the formation of the active-site loop bundle.
The L2’ loops from the opposite sides of the dimer form an anti-parallel structure with a
nearly 90° crossing angle. The residues with the closest approach are the two R210
residues, with a C#-C# distance of 5.5Å (Figure 18 A).

48

4D)

49)
45)

456)

456)

?)
)
)
)
)

1)
)
)
)
)

?)456)
@5AB<)

@5AB<)

<ABB)
1)456)
<59C)

1)456)
?)23'+%)

787)9:9;)
<!8<!)=:>;)

@5AB<)

1)23'+%)

*$,+0%$/)*+,-(./$)

!"#$%&'()*+,-(./$)

Figure 18: Design of a reductant activatable caspase-7
The allosterically inactivated caspase-7 dimer consists of two chains (A chain, green; B chain,
blue). (A) An introduced disulfide between R210C residues on the two chains (white and yellow
spheres) is designed to lock the protein into the inactive conformation by keeping the L2’ loops in
the down conformation. Formation of this disulfide would result in a covalently crosslinked smallsubunit homodimeric species. (B) Pairs of native cysteines (C100 and C246, blue and yellow
sticks) are computationally predicted to form disulfides on each side of the dimer. These disulfides
would drive formation of a large subunit-small subunit crosslinked species.

We modeled pairwise mutations to cysteine for all residues in the L2’ loops then used the
MODIP89 server to score the probability of forming various disulfides. MODIP scored an
R210C-R210C disulfide in the C category on a scale of A (most favorable) to F (least
favorable). This intermediate score may be related to the fact that all C# positions are
fixed during MODIP modeling. The L2’ loop is necessarily flexible, as it undergoes
significant rearrangement during the caspase lifecycle, thus a score of C may still indicate
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a favorable interaction. In contrast, a second potential native disulfide, which we
subsequently observed crystallographically (Figure 19), was scored as an A.
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Figure 19: Observation of a C100 and C246 disulfide.
(A) A C100-C246 disulfide is visible between the large and small subunits in a crystal structure of
caspase-7 with an uncleavable peptide inhibitor bound in the active site. 2Fo-Fc density contoured at
1.0 ) is shown. (B) Sequence alignment of caspases in the region of C100 and C246. The potential
disulfide linking the large and small subunits is unique to caspase-7.

Our first design attempt was the substitution R210C. Purification of the single R210C
variant was not successful, due to low protein yields. We speculated that the formation of
mixed disulfides may have contributed to low protein yields.
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We found that removal of one native cysteine, which improved protein yields and eased
analysis was essential. Caspase-7 is unique among caspases in that it contains a potential
disulfide interaction between residues 100 (large subunit) and 246 (small subunit) (Figure
18 B). We engineered out the native C100-C246 disulfide by making the C246S
substitution. C246S had similar catalytic parameters to wild-type (Table 1). We
combined this with the disulfide locking R210C substitution. The doubly substituted
variant (R210C/C246S) had good catalytic activity and exhibited KM and kcat very similar
to wild-type (Table 3, Figure 20).
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Figure 20: Kinetics curves for caspase-7 WT, C246S, R210C/C246S
Raw RFU (relative fluorescence unit) data for substrate titration of caspase-7 WT, C246S, and
R210C/C246S in both 5 mM BME and 10 mM DTT. Michaelis-Menten curve fitting was applied
to determine kcat and Km with protein concentration held constant.
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Table 1. Kinetic parameters for caspase-7 variants
5 mM BME

10mM DTT

WT

C246S

R210C C246S

WT

R210C C246S

kcat (s-1)

0.36 ± 0.01

0.33 ± 0.01

0.40 ± 0.01

2.42 ± 0.07

2.46 ± 0.06

Km (µM)

23.98 ± 2.02

21.46 ± 2.77

22.65 ± 2.85

41.87 ± 4.15

39.36 ± 3.42

Kinetic parameters are based on substrate titrations measured from independent triplicate dilutions of
substrate on two days.

!
Table 3: Kinetic parameters for caspase-7 WT, C246S, R210C/C246S
Measured kinetic parameters for WT, C246S, and R210C/C246S do not show significant variances,
suggesting the mutations do not have an effect on enzyme kinetics. Similarly, while overall
enzymatic rate increases in the presence of higher concentrations of reductant, the increase is
statistically identical between WT and R210C/C246S.

The observed differences between 5 mM and 10 mM DTT can be attributed to the fact
that DTT has a higher reduction potential. In cysteine-histidine proteases an oxidized
cysteine would disable the catalytic activity, as mechanism is dependent on the histidine
abstracting a proton creating a reactive thiolate. The stronger reductant present eases the
formation of this thiolate species and helps to facilitate the reversal of the tetrahedral
covalent intermediate by H2O increasing the apparent activity of caspase-7.
Observation of the designed disulfide dimer.
The variant R210C/C246S is designed such that mildly oxidizing conditions should drive
formation of a disulfide, locking the two L2’ loops together across the dimer interface
and allosterically inhibiting caspase-7. Because the L2’ loops are the N-termini of the
small subunits, formation of the inactivating R210C-R210C disulfide will generate
covalent small subunit dimers. To measure formation of small-subunit dimers, we
exposed wild-type or R210C/C246S caspase-7 to native (reducing conditions) or mildly
oxidizing conditions (300 µM cystamine). The bands on a denaturing acrylamide gel
were unambiguously identified by a combination of mass spectrometry and
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imunoblotting with antibodies specific for the large or small subunits of caspase-7
(Figure 21, Figure 22).
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Figure 21: Incubation of caspase-7 R210C/C246S under oxidizing condition results in formation of a
unique disulfide between the two small subunits of caspase-7.
(A) Domain structure and molecular weights of WT or R210C caspase-7. (B) WT and
R210C/C246S caspase-7 were incubated in native conditions (2 mM DTT) or in oxidizing
conditions (300 µM cystamine) then analyzed on a coomassie-stained SDS gel or by western blot
with a caspase-7 anti-large subunit or anti-small subunit antibody. The three gels were merged with
the anti-large subunit signal colored blue and anti-small subunit signal colored red. The two small
subunit bands in the native conditions are alternatively cleaved versions of caspase-7, with
cleavages at naturally occurring residues 199 or 207.

Caspase-7 has two major auto-activating cleavage sites in the intersubunit linker at
residues 198 and 206 (Figure 21 A). In wild-type caspase-7 the intersubunit linker
(residues 199-206) is removed so the prodomain-deleted large subunit is composed of
residues 24-198 and the small subunit consists of residues 207-311. For our designs, we
used a construct that allows constitutive expression of the two-chain (active) form of
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caspase-7. R210C/C246S caspase-7 was produced as two polypeptides of residues 1-198
and 199-311. In addition to removal of the prodomain, the large subunit was also
processed at a minor cleavage site (residue 192, which has been extensively probed by
Denault and co-workers90) generating some large subunits composed of residues 24-192.
The small subunit of R210C/C246S appears in two forms (Figure 21 A,B), both with the
intersubunit linker (residues 199-311) and without the intersubunit linker (residues 207311). Under oxidizing conditions the C100-C246 disulfide can be observed in wild-type
caspase-7 as a large-small dimer as a minor product. Importantly, the expected smallsubunit (small-small) dimer band is strongly formed in R210C/C246S, but is not
observed in wild-type caspase-7. This demonstrates that the designed dimer forms as
expected but spurious and random disulfides do not form. The small-small dimer could
also be readily observed by mass spectrometry (Figure 22, Table 4).
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Figure 22: The small-small subunit dimer can be observed by mass spectrometry
R210C/C246S was incubated in the presence or absence of oxidant (1.5 mM cystamine) then
analyzed by mass spectrometry. (A) In the absence of oxidant clear ions for the large subunit (blue)
and the two cleavage variants of the small subunit (red, residues 199-311; green, 207-311) were
observed. (B) In the presence of oxidant, identical ions were observed for the large subunit (blue).
For the small subunits twice as many ions were observed indicating a doubling of the molecular
weight due to dimerization of the 199-311 species (red). A hybrid small subunit dimer between the
199-311and the 207-311 species (green) is also observed.
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Table S1. Tabulated deconvoluted ions from the R210C/C246S mass spectra collected in the
presence and absence of oxidant. Observed protein masses and corresponding mass to charge
(m/z) states are listed. All deconvolutions were gated for masses between 10kD and 30kD.
No Oxidant
Mass (avg.)
19718.0

Oxidant

m/z

Charge (z)

705.2
731.3
759.4
789.7
822.6
858.3
897.3
940.0
986.9
1038.8
1096.4
1160.9
1233.4
1315.4
1409.5
1517.8
1643.9
1793.6

28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11

730.6
773.5
821.8
876.6
939.1
1011.3
1095.4
1194.9
1314.3
1460.2
1642.7

18
17
16
15
14
13
12
11
10
9
8

Mass (avg.)
19718.7

13133.1

m/z

Charge (z)

705.3
731.3
759.4
789.8
822.6
858.3
897.3
940.0
986.9
1038.8
1096.5
1160.9
1233.5
1315.5
1409.5
1517.8

28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13

730.6
751.6
773.4
796.9
821.8
848.3
876.5
906.7
939.1
973.8
1011.2
1051.6
1095.4
1143.0
1194.9
1251.8
1314.3

36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20

26265.7

Table 4: Tabulated MS deconvolution ion data of R210C/C246S
Tabulated deconvoluted ions from the R210C/C246S mass spectra collected in the presence and
absence of oxidant. Observed protein masses and corresponding mass to charge (m/z) states are
listed. All deconvolutions were gated for masses between 10kD and 30kD.
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Under reducing conditions only monomeric large and small subunits of R210C/C246S
were observed. Under oxidizing conditions, small-small dimers were readily observed,
further confirming the success of the design. Interestingly, both homo-dimers and heterodimers of the two small subunit cleavage variants are observed. For this design to be fully
successful it is essential that small-small dimers can strongly form, inactivating
R210C/C246S, and subsequently be reduced, resulting in the return of full activity.
Inactivating disulfide forms reversibly
R210C/C246S can be inhibited under mildly-oxidizing conditions (Figure 23) in a
manner that is consistent with observation of the small subunit dimers (Figure 21, Figure
22).
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Figure 23: Disulfide bond formation induces the allosterically inactive state of caspase-7, which can
be reactivated by the presence of reductant.
Caspase-7 proteolytic activity was monitored in the presence of increasing concentrations of
oxidant (cystamine). (A) Oxidation of the R210C is capable of inactivating R210C/C246S at much
lower concentrations than the active site can be oxidized in wild-type caspase-7 (WT). (B) In the
presence of reductant (10 mM DTT) full activity is recovered. Data is based on activity assays
measured from independent duplicate data sets on two separate days.

Inactivation of oxidized R210C/C246S can be monitored either directly by assaying
cleavage of a fluorescence substrate (Figure 23), or indirectly by observing that cleavage
at the 192 site is slowed only under oxidizing conditions (Figure 21). We tested the
reversibility of R210C/C246S inhibition by incubation in reductant at a roughly
intracellular redox potential. R210C/C246S was able to fully recover from oxidationinduced inhibition. Inhibition of wild-type caspase-7 is likely the result of mixed
disulfide formation between the catalytic cysteine and the cystamine oxidant, which has
previously been reported91 and is also fully reversible under these conditions.
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We observed caspase-7 R210C/C246S in an active conformation in the crystal structure.
There are two possible explanations for why the oxidized form of the enzyme was not
observed. One is that the latent presence of month old DTT (2mM) from the purification
was not sufficiently overwhelmed by 1.5 mM oxidant, as was seen in the mass
spectroscopy experiment. This would have resulted in the reduction of the disulfide
during crystallization, though we consider this unlikely. A second possibility is that the
disulfide was reduced by synchrotron radiation, and we discuss that possibility here.
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Figure 24: Caspase-7 R210C/C246S can reversibly attain the active conformation.
(A) Oxidized R210C/C246S was crystallized but was reduced prior to or during data collection.
Reduced caspase-7 R210C/C246S (3R5K, green) attains a conformation like that of WT caspase-7
bound to substrate (1F1J, purple) with L2 and L2’ in the up conformation interacting across the
dimer interface. This is in contrast to the allosterically inhibited conformation of caspase-7 (1SHJ,
yellow) in which the L2’ loop is folded over the allosteric site and the two L2’ loops make contact
with one another. (B) The catalytic residues H144 and C186 are in a conformation that is close to
ideal for catalysis. Additional 2Fo-Fc density contoured at 1 ) density was observed in the S1
pocket was modeled as a formate molecule from the crystallization solution. The density around the
catalytic cysteine (C186) was larger than one cysteine residue. It was best modeled as two cysteine
conformations each with 50% occupancy. (C) 2Fo-Fc density contoured at 0.8 ) for R210C. (D, E)
2Fo-Fc density contoured at 1 ) for R210C/C246S (D) and wild-type (E) caspase-7

59

We solved the structure of R210C/C246S in two independent crystals (Table 5). In the
structures from both of the crystals it was clear that the R210C disulfide had been
reduced. We were pleased to see that as was the case for chemical reductants, the R210CR210C disulfide could be reversed in the crystal by ionizing radiation, allowing the L2’
loop to adopt the active conformation (Figure 24 A). This was not surprising, as ionizing
radiation has been reported to reduce disulfides92. The radiation applied to the crystal at
the APS synchrotron x-ray source has a flux on the order of 1019 photons/sec/mm2. It has
been reported that sources with flux of 1015 photons/sec/mm2 can induce disulfide
reduction and global protein relaxation93. In an attempt to observe the disulfidecontaining form of R210C/C246S we limited x-ray exposure to one second with the APS
24-ID-C x-ray beam attenuated to 7% and solved the structure using the minimal data
necessary (30 degrees of data, 20 frames, 1 sec/frame, 83% completeness). Even with
only 20 seconds total exposure to the crystal, we were unable to observe any oxidized
disulfide, suggesting that the inactivating disulfide is quite labile. We can roughly
estimate the lability of the R210C disulfide by comparison to other caspase-7 disulfides
that do withstand x-ray interrogation. DICA and FICA, which bind to caspase-7 via
disulfides with C290, withstand x-ray radiation and are visible in the crystal structure42.
The disulfide linking the large and small subunits of caspase-7 (C100-C246) also
withstands x-ray radiation under certain conditions (Figure 19). Thus of the three types of
disulfides observed to date in caspase-7, the R210C disulfide may be the most labile. All
caspase-7 structures observed to date show the same crystal packing arrangement.
Regardless of the loop conformation, the active-site loops always point toward the large
solvent channels. Thus it is not surprising that the loop reorganization we observed
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between the oxidized, disulfide-locked R210C/C246S and the reduced, unlocked form
can be accommodated and interconverted within the same crystal.
Diffraction Data
Wavelength (Å)
Resolution Range (Å)
Oscillation Range per frame
Measured reflection (n)
Unique reflections
Completeness (%)
Redundancy
<I/!I>
Space Group
a = b (Å)
c (Å)
# = " (°)
' (°)
Rsym

Native Data set 1
0.9792
48-2.86
1.0°
106848
20763
99.2 (97.2)
5.2 (4.7)
16.0 (2.7)
P3221
89.85
185.91
90
120
12.7 (69.6)

Refinement Statistics
Atoms (n)
Water molecules
Rwork (%)
Rfree (%)
RMSD bond length (Å)
RMSD bond angle (°)
Average B-factor (Å2)

3900
103
18.81
25.13
0.010
1.197
58.93

Native Data set 2
0.9792
48-3.1
1.5°
28496
17353
83.6 (87.9)
1.6 (1.6)
16.4 (2.0)
P3221
89.98
185.11
90
120
9.1 (69.4)

Table 5: Crystallographic and Refinement parameters of R210C/C246S
Data in parenthesis are for the highest resolution shell

Catalytic site geometry
The reduced form of R210C/C246S is in a conformation that is primed for substrate
binding (Figure 24). Typically, in the absence of an active site ligand, the L2’ loop is in a
catalytically inactive conformation39 similar to the allosterically inhibited form42 (Figure
24 A, yellow spheres). In our structure the presence of formate at high concentrations
(2.1M) in the crystallization buffer is sufficient to nucleate formation of the substrate-
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binding conformation (Figure 24 A, green and purple spheres). Here formate serves as a
surrogate for the aspartic acid that normally occupies the S1 pocket (Figure 24 B).
Because structures of caspases in the active conformation have always been solved in the
presence of the covalent inhibitor, a structure of WT caspase-7 with formate in the active
is not available. Based on evidence in which a similar phenomenon has been observed for
caspase-1 where malonate assists in refolding caspase-1 and serves as a mimic for
aspartic acid bound in the active site94. Although the structure of wild-type caspase-7 has
not been determined in formate-containing conditions, we believe that WT protein would
exhibit a similar substrate-binding groove structure, nucleated by formate, in the
presence of high concentrations of formate.
In R210C/C246S the catalytic dyad (H144 and C186) are in a closer to optimal
arrangement for catalysis (3.6Å) that has not been observed before in caspase-7. Papain,
another cysteine protease, has been reported to have a cysteine-histidine distance of 3.2Å
in a high resolution crystal structure, while computational methods have determined 3.03.3 Å to be the optimal distance for catalysis95,96. All previous caspase-7 structures in
which the substrate-binding loops are ordered relied on covalent modification of the
catalytic cysteine37-39,41,42,61,88 and therefore had H144-C186 distances that were too great
(typically ~5.5Å) to support necessary proton abstraction. The density for the catalytic
thiol is not unambiguous. We have modeled this density in several ways including
positioning a water in one lobe of the density. The unfavorable angle of the hydrogen
bonds for water suggested to us that this is not a water molecule. Therefore, we
concluded that two conformations of the catalytic thiol may be a more accurate
representation. We have thus modeled the density as a 50% mixture of two thiol
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conformations (Figure 24 B) though the thiol position nearest the histidine is 35° from an
ideal rotamer. R210C is near the N-terminus of the small subunit. In caspase-7, it is
typically only possible to observe residues starting at residue 212, due to disorder of the
N-termini. It is therefore not a surprise that the density is weak, nevertheless we were
able to visualize and build R210C (Figure 24 C). It was also possible to visualize the
substitution in our design, C246S (Figure 24 D). C246S is in a different conformation
than C246 locked into a disulfide by an uncleavable peptide (Figure 24 E).

Discussion
The disulfide bond is a useful protein-engineering tool since it can form covalent, redoxcontrollable bonds at discrete locations from naturally occurring amino acids. Since the
advent of site-directed mutagenesis, introduction of disulfide bonds has been a well-used
tool for controlling protein conformation. Engineered disulfides have been used to
examine functional mechanisms97,98, stabilize proteins99,100, understand allosteric
coupling101,102 and even to trap transition states103. Redox reversible switches have been
developed in a number of proteins including measles virus F protein104, malate
dehydrogenase105, integrins106, kinesin107 and the OxyR transcription factor108, among
many others. We sought to build upon this rich history and design allosterically
controlled caspases, a class of proteins capable of regulating life and death of cells.
The criteria that guided the rational design of redox activatable caspase-7 included: (1)
motion of the L2’ loops should be restricted by disulfide-bond formation; (2) the catalytic
efficiency of the untreated protein should mirror that of the wild-type enzyme; (3) full
oxidation of the disulfide should result in full inhibition of caspase-7 under extracellular
redox environments and (4) introduction into intracellular reducing conditions should
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result in full recovery of proteolytic activity. Caspase-7 is a dynamic protein in which
loop arrangement plays a key role in activation of the enzyme. In our designed variant
R210C/C246S, we placed the inactivation switch at the heart of a critical, active-site loop
bundle. In the down confirmation, with the L2' loop pinned over the allosteric cavity, the
substrate binding groove is not formed so the protein is unable to bind substrate or
catalyze the peptide cleavage reaction. By placing the disulfide over the allosteric site at
the intersection of the L2’ loops, we can enforce a naturally occurring inactive state using
native-like redox conditions. In R210C/C246S we fulfilled all of the design criteria. In
vitro activity results and the observation that oxidation of the R210C disulfide could also
prevent self-processing at the minor D192 processing site both suggest ready inhibition
by disulfide formation. The crystal structure of R210C/C246S that was first oxidized and
then re-reduced in the crystal demonstrates the successful reversibility of our design.
Finally the observation of small-subunit dimers points to the inhibition mechanism by
covalent locking of the L2’ loops.
Engineering in redox switches in a critical region like the active-site loops bundle could
be a risky proposition. We had previously interrogated residues 211-215 in the L2’ loop
and found that they were amenable to substitution88. By extension, we hoped that R210
would likewise be amenable to substitution without negative functional effects.
Fortunately, this was the case. All caspases have mobile active-site loops. Although this
endeavor used caspase-7 as a template, the approach of pinning the L2’ loops should be
applicable for any caspase since the active site loops of all caspases are mobile prior to
the binding of substrate. Residue 210 is not highly conserved so this position should be
amenable to this substitution across the family. Intriguingly, residue 210 is natively a
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cysteine in caspase-3, begging the question of whether caspase-3 uses formation of this
potential disulfide as part of its unique regulatory mechanisms. In a very high resolution
structure of caspase-3, the L2’ loop is seen to wrap around the opposite half of the dimer
with C210 attaining two solvent accessible conformations33. Because caspase-3 has not
been crystallized in the absence of a substrate-mimic nor in the allosterically inhibited
conformation, the best model of what this region might look like is the allosterically
inhibited structures of caspase-7 where the 210 residues make the closest approach. Thus
it may be possible to make a loop-locked version of caspase-3. It is intriguing to envision
controlling the activity of an engineered, constitutively active and uninhibitable version
of the caspase-3 zymogen34 using our loop-locking design. Thus there are many
possibilities for designing loop-locked caspases. Induction of apoptosis by treatment with
a variety of allosterically loop-locked caspases should therefore be possible given
appropriate means of delivery.
Breakthroughs in targeted nanoparticle and polymer design have begun to make delivery
of a much wider range of protein-based drugs feasible (for review109). Active targeting of
nanoparticles, polymers, dendrimers, and nanogels can be achieved using disulfide
functionalization, with the prospect of delivering encapsulated payloads including both
small molecules and proteins. The combination of caspase-7 R210C/C246S with a redoxtriggered delivery vehicle is therefore an intriguing prospect. If R210C/C246S were
encapsulated in a redox-activable nanocarrier, in the relatively oxidizing extracellular
environment, R210C/C246S should remain inactive and inaccessibly encapsulated. Upon
introduction into the reducing cytosolic environment, the redox sensitive delivery device
would release R210C/C246S (Figure 25). Liberated R210C/C246S could then likewise
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be reduced, regain function and activate apoptosis, leading to cell death. This scheme is
particularly promising in cancers and proliferative disorders, where suppression of
apoptosis is nearly always a contributor to the evasion of cell death pathways.

Figure 25: Delivery scheme for caspase-7 R210C/C246S
Capase-7 R210C/C246S is amenable for use with delivery vehicles (diamonds). We have designed
the R210C/C246S version of caspase-7 so that under oxidizing extracellular conditions caspase-7 is
inactive. Upon entry into the cell, reducing intracellular conditions break the R210C disulfide
yielding active caspase-7, which can cleave intracellular targets leading to apoptotic cell death.

Materials and methods
Caspase-7 mutant generation, expression and purification
Wild-type caspase-7 was expressed from a construct encoding residues 1-303 plus
codons for the two amino acids LE, then a six-Histidine tag contained in the plasmid
pET23-b (AmpR) plasmid110. Expression of caspase-7 variant R210C/C246S was carried
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out in a constitutive two chain expression system27. Residues 1-198 were followed by a
TAA stop codon, a second ribosome binding sequence, and residues 199-303, plus
codons for the two amino acids LE and a six-Hisidine tag contained in the plasmid
pET23-b (AmpR). Variants in the protein were generated using QuikChange (Stratagene)
site-directed mutagenesis. The recombinant protein was expressed in E. coli in 2xYT
media grown for 18 hours after induction with 1 mM Isopropyl "-D-1thiogalactopyranoside at an OD 600 of 0.6.111 Wild-type and mutant caspase-7 variants
were purified using Ni-affinity liquid chromatography (HiTrap Chelating HP, GE). After
binding of protein to the affinity column, the protein was eluted with a step gradient from
2 mM imidazole to 250 mM imidazole. Protein was diluted to 50mM NaCl and then
purified using a Macro-Prep High Q ion exchange column (Bio-Scale Mini 5mL, BioRad) with a linear gradient from 50 mM to 500 mM NaCl in 20 mM Tris buffer pH 8.0,
with 2 mM DTT. Protein eluted in 120 mM NaCl and 20 mM Tris pH 8.0 was assessed
for purity by SDS-PAGE to be greater than 98% pure, and stored in elution buffer at 80°C.
Caspase activity assays
Enzyme concentrations were determined by active site titration with covalent substrate
DEVD-CHO (N-Acetyl-Asp-Glu-Val-Asp-Aldehyde, Enzo Lifesciences) in caspase
activity buffer containing 100 mM Hepes pH 7.0, 10% polyethylene glycol 400, 0.1%
CHAPS, 5 mM "-mercaptoethanol, and 5 mM CaCl2 using the flourogenic substrate,
DEVD-AMC (N-acetyl-Asp-Glu-Val-Asp (7-amino-4-methylcoumarin), Enzo
Lifesciences), Ex365/Em495. Active site titration samples were incubated over a period
of 2 hours in 120 mM NaCl 20 mM Tris pH 8.0 at nanomolar concentrations. Optimal
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labeling was observed when protein was added to DEVD-CHO solvated in DMSO in 96well V-bottom plates, sealed with tape, and incubated at room temperature. 22.5 µL and
90 µL aliquots were transferred to black-well plates in duplicate, and assayed with 50fold molar excess of substrate. For kinetic measurements, 100 nM protein was assayed
with the range of 0-500 µM DEVD-AMC over the course of seven minutes. Assays were
performed at 37°C in 25 µL and 100 µL volumes in 96 or 384 well microplate format
using a Molecular Devices Spectramax M5 spectrophotometer. Initial velocities versus
substrate concentration were fit using Prism software (Graphpad Software) to determine
kinetic parameters Km and kcat.
Enzyme activity recovery assays were carried out using WT and R210C/C246S mutant
protein buffer exchanged to remove DTT into pH 7.5 10 mM sodium phosphate buffer
using Viva Spin 3K concentrators (Sartorius Stedim Biotech,). Working at intracellular
reduction conditions in vitro proved challenging, due to the propensity of caspase-7
active site to form mixed disulfides with glutathione. As a surrogate, we selected
cystamine as the oxidant and dithiolthreitol or 2-mercaptoethanol as reductants. The
reduction potentials of these four redox systems have been shown to be similar112,113.
Protein was incubated in 96-well format in a range of cystamine concentrations (300 µM
- 5 µM; 0 µM control) for a period of one hour. Half the volume was subsequently
transferred to conditions with a final concentration of 10 mM dithiothreitol (DTT) and
assayed for activity. DTT’s redox chemistry is at equilibrium with cystamine at pH 7.9,
supporting our use of 10 mM DTT as an adequate substitute for a highly reducing
intracellular environment.
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A similar ratio of oxidant to protein was used to treat caspase samples for caspase activity
assays, immunoblot detection, mass spectrometry and crystallography. Caspases were
then diluted to the concentration appropriate for the individual type of analysis.
Gel electrophoresis and immunoblot detection
WT and R210C/C246S protein was buffer exchanged using above method into pH 7.5 10
mM sodium phosphate buffer, then divided into two samples and incubated in the
presence or absence of 300 µM cystamine for 2 hours. Samples for non-reducing gel
electrophoresis were boiled for 10 minutes in Gel Loading Buffer (New England Biolabs)
lacking DTT, and loaded onto 16% polyacrylamide gels. Immunoblots of the
subsequently separated proteins were performed using antibodies specific for caspase-7
large subunit (SIGMA Monoclonal Anti-caspase-7 C1104) and small subunit (SIGMA
Anti-caspase-7 PRS3465) and compared against known size standards (Kaleidoscope
protein marker, BIO-RAD). False color merged photographs were generated by contrast
enhancement then selective color replacement (Adobe Photoshop).
Protein mass spectroscopy
Protein for mass spectrometry was prepared at 18 µM in 120 mM NaCl, Tris pH 8.0 and
2 mM DTT with or without 1.5 mM cystamine. Mass spectra were acquired on a QStarXL (MDS Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight instrument. Reverse
phase liquid chromatography (Agilent 1100 LC) using a C4 column was utilized to desalt
and separate excess cystamine. Column output was infused directly into the ESI source at
a rate of 0.5ml/min using N2 as a nebulizing gas. Protein was eluted over a 10-minute
gradient from 0%-100% acetonitrile and monitored using UV and TIC. A single protein
peak eluted between 17-18 minutes at the end of the gradient. Data was analyzed using
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Analyst QS (Applied Biosystems) with BioAnalyst extensions. All spectra
deconvolutions were gated for proteins between 10 kD and 30 kD, with m/z ratios
between 700 and 1700. The Mass spectrometers are housed in the Mass Spectrometry
Center of the University of Massachusetts at Amherst.
Caspase-7 R210C/C246S crystallization and x-ray data collection
To prepare R210C/C246S crystals, protein in a buffer containing 120 mM NaCl and 20
mM Tris pH 8.0 was concentrated using Millipore Ultrafree 5K NMWL membrane
concentrators (Millipore) to 6.3 mg/mL as assessed by absorbance at 280 nm. Cystamine
was added to a final concentration of 1.25 mM. Crystal trays were setup at room
temperature and grown in 3 µL hanging drop with mother liquor consisting of 2.1 M
sodium formate, 300 mM and sodium citrate pH 5.0 in a 2:1 ratio of protein to mother
liquor. Crystals grew to a maximum of 180 µm in 3 days at 20 degrees. Crystals were
cryoprotected in 20% ethylene glycol in mother liquor with a 60 second incubation, then
frozen by rapid immersion in liquid N2. Data were collected using synchrotron radiation
at APS 24-ID-C over 90 frames with 1° oscillations and showed diffraction data to
2.86Å. Indexing and integration were carried out with MAR XDS114. Data were Scaled
using SCALA74. Data for the low radiation damage crystal were collected using with 1.5°
degree oscillations. These data were indexed and integrated using HKL200073 and the
data were scaled using SCALA74.
Structure determination
Phase information was obtained by molecular replacement using 1F1J as the search
model with residues corresponding to L2' omitted during searches with PHASER115.
Removed residues were rebuilt into unambiguous density using COOT116, then refined
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using Refmac117 restrained refinement. Water and formate molecules were inserted
manually and checked for stereochemical appropriateness. The final refined model
contains residues 57–196, 210–303 for chain A and 357–496, 510–605 for chain B. 103
water molecules are assigned chain O, and 7 formates assigned chain F.
Coordinates have been deposited in the PDB with accession code 3R5K

71

CHAPTER IV

COMPUTATIONAL PROTEIN RE-DESIGN USING EGAD
Abstract
Current tools employed in the study the role of individual caspases in apoptosis lack
specificity, and thus a novel approach by an orthogonal effector will address such a
limitation. In this work we propose to develop an orthogonal switch technology based on
a computational redesign of the allosteric site at the dimer interface in caspase-7. This
will allow for specific control over the function of caspase-7. Such a technology would
facilitate the study of caspase-7 target substrates in cellular cultures, without necessitating
the use of potentially misleading knock-out variants. The use of a computational system
allows for the rapid sampling of millions of possible amino acid and molecule
permutations on very short timescales. This high throughput sampling has allowed rapid
in silico evolution of a small molecule binding site which was the objective of this part of
the thesis. In the future, these designs can be tested by enzymatic studies and
crystallographic methods.

Introduction
Design of orthogonal controls would address the lack of specific inhibition tools available
for the study of various protein families. The ultimate goal of this approach is to develop
a robust design and validate the technology on a whole range of caspases. This will allow
us ultimately to spread this technology to other allosterically controlled proteins. The
goal of this project was to use computational protein design methods118 to redesign the
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cavity at the interaction surface of two caspase-7 monomers and introduce specificity for
a small molecule which would act as an allosteric inhibitor for that particular caspase.

Figure 26: Small molecule effector placed ideally in allosteric cavity.
A small molecule (doxycycline) has been modeled into an ideal position in the allosteric cavity of
caspase-7. The allosteric switch tyrosines (purple spheres) are sterically blocked by the small
molecule from adopting the catalytically competent conformation.

The allosteric inhibition of caspase-7 by covalently tethered molecules has been
studied42,81. The next logical step is to use a non-covalent reversible interaction to
inactivate the protein. Using computational design as a low penalty, high throughput
iterative design screen, we can combine established molecular biology methods, along
with crystallography, to develop a model-to-protein-to-crystal design process of the
protein. This will iteratively lead to a new protein variant that can be controlled
orthogonally by means of a small molecule used in the design. Our computational design
will begin with known crystallographic structures of caspase-7, which will be optimized
for non-covalent binding of a tetracycline-class antibiotic molecule. In this optimization,
the amino acid sequence that can best recognize the small molecule is computed. After
the in silico design, the protein can be expressed in E. coli and purified for biochemical
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characterization and crystallization. The resultant crystallographic data will allow
refinement of computational models based on actual structural information, and perhaps
elucidate new pathways for allosteric inhibition by small molecules.
Directed evolution is the best analogue for a computational design process. It must be
said that there have been more successes with using directed evolution to engineer in new
functions to proteins. However, as opposed to directed evolution, computational designs
allow for screening of 1024 (13 sites per monomer, 17 potential amino acids at each
position; 2617 ≈ 1024) potential variants per simulation. To effectively screen similar
numbers of variants using directed evolution is impossible with current technologies,
which allow for screening of 109-1013 variants maximally. Even to screen these smaller
numbers of variants would require the development of a robust reporter of caspase
inactivation, combined with rapid screening methodologies. However, the use of such
technologies would require significant additional capital and time investment as
compared to a computational trial. Thus computational protein re-design is the most cost
effective rapid initial screening method for the introduction of new binding motifs.
Furthermore, the prospect of combining directed evolution with computational design can
increase the likelihood of success dramatically.
Success in protein design and redesign efforts lies in the availability and openness of the
design platform. Many efforts have been duplicated in the field of computer-based
protein design, however, the growing popularity of the open source software movement
may stem this tide. Programs like DEZYMER119 have been historically difficult to obtain,
with source code not being made available. In the absence of the original source code, the
inner workings of the energy functions and parameterization are hidden from the
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operators, keeping the software more single purpose. However, the availability of source
code does not automatically guarantee a better working environment. Rosetta56, by far the
most popular current protein-design package, does offer source code, however the
documentation of the source code is reportedly minimal, leaving the user to reinvent the
wheel in the process of customizing the software for a novel purpose. On the other hand,
EGAD118, while not in active development, has been released freely, with extensive
documentation to allow for easy customization by novice computational chemists. In
addition, at the time this project was implemented, EGAD was one of the few programs
that could design proteins against a small-molecule ligand. It is therefore important to not
only consider the success of the tool used for protein design, but also the availability of
documentation.

Existing EGAD toolkit
EGAD, or EGAD!, a Genetic Algorithm for Protein Design, was developed initially
Navin Pokala under the direction of Tracey Handel118, and has since been updated to
EGAD Library, by Arnab Chowdry120. EGAD Library is based on EGAD’s force-field
implementation and according to the application’s literature, “is intended for end users
with programming experience, written in C++, for the development of new protein design
applications.” As an open source and well-documented application, EGAD allows novice
programmers to develop and extend the current toolset for the users particular interest.
This full access to the development of the program is very advantageous over other more
black-box suites, as features and bugs can be worked out. The use of this method allows
for a high throughput design from the computational model to the expressed protein, and
ultimately the solved crystal structure of the allosterically inhibited caspase.
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EGAD’s computational approach relies on structural protein data in the form of a set of
coordinates in a PDB file along with the structural data of the small molecule. The initial
starting location of the small molecule, henceforth referred to as the ligand, in relation to
the protein is preset by the user. Molecular visualization programs such as PyMol79 or
COOT116 can be used to design this initial small molecule placement based on existing
knowledge of the allosteric switch in caspase-742. The selection of residues comprising
the potential binding cavity is similarly chosen. A variable residue can either have full
mutability, in that EGAD can choose the best amino acid identity, save for Gly, Pro, Cys,
and rotamer for that particular position. The second option is to maintain amino acid
identity at a position, while allowing that particular position to select from the rotamer
library to optimize the position.
The selection of ligand is restrained by two criteria. First, desired ligand should have no
appreciable effects on wild-type caspase-7, and secondly, the ligand must be amenable to
computational design in that the molecule has few rotatable bonds and the molecule must
be of appropriate size for the cavity. One potential family of allosteric effectors is the
tetracycline antibiotic family. Preliminary caspase-7 inhibition studies were carried out in
the Hardy lab to determine possible tetracycline derivatives that are appropriate for use in
design. Besides tetracycline, doxycycline, demeclocycline and minocycline were tested
for their inhibitory effect on the wild type caspase-7 protein.
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Figure 27: Effects of tetracycline analogs on caspase-7 activity.
Wild-type caspase-7 was incubated with increasing concentrations of the indicated inhibitors for
one hour. The activity of caspase-7 was then tested in a kinetic cleavage assay using the
fluorometric substrate DEVD-AMC. The amount of inhibition is relative to a DMSO control.

(Figure 27). Demeclocycline showed inhibition of the protein at relatively low
concentrations through an undetermined mechanism, and so was ruled from further
investigations. Doxycycline and minocycline both had similar inhibition curves to that of
tetracycline and thus were considered for further study using EGAD. Doxycycline has
been chosen as the most likely candidate for allosteric effector.

Figure 28: Potential small molecule effectors
The length of the potential small molecule effectors is of interest since the effector must effectively
fill the cavity of caspase-7.
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To produce a small-molecule starting model for future designs, the low energy structure
of each small molecule was determined computationally using Hartree-Fock type ab
initio calculations to the RHF-6- 31+g basis set using Gaussian 03121. The reliability of
this calculation was determined by the calculation of the minimum energy structure of
tetracycline, and comparing it to that of a solved crystal structure that included
tetracycline in complex with the ribosome, with the two results being very similar.

EGAD Computation Setup
EGAD is a command line driven program with no graphical user interface, and so all
commands and input must be hand coded into input files. The input file generation for
EGAD is by far the most time consuming of steps prior to calculations. The small
molecule’s molecular description consists of a ligand input file and a ligand parameter
file, which contains all the atomic coordinates, the atom types, atom charges, and interatomic connectivity. Atomic coordinates are represented as X, Y, Z and are in the same
space as the protein. Atom type is for the OPLS force-field122 and the atom type is
assigned manually at the discretion of the user. The atom type depends on the atomic
environment in which the atom resides. Atomic connectivity is self-explanatory and
charges are calculated during the energy minimization step of the geometric optimization
in the ab initio calculation of the structure of the ligand. Rotatable bonds can be described
in EGAD, however this feature is of limited use as the bonds can only be described as a
set of three rotations about a fixed atom.
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Protein PDB
Associated Input file
includes other input file
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Ligand Input
Parameters
Atomic coordinates
Atom type
Ligand placement in space
Rotation, translation allowances

Energy Tabling
Minimizer

Output PDB

Figure 29: EGAD operation flow
Files containing atomic coordinates and atomic descriptors for both the protein and small molecule
ligand are input into EGAD for energy tabling. The energy table is then loaded into an energy
minimizer, which uses DEE and Monte Carlo methods to search for an energy minimum. Once
sufficient solutions are found, the data is then output as coordinate files in the form of PDBs.

The second file that describes the ligand is the ligand input file. This file calls the ligand
parameter file at the start of the calculation, and includes the coordinates of the centroid
of the molecule. The centroid is calculated by finding the mean of all the discrete
coordinates of the atoms within the ligand. The input file includes the variables for
allowed ligand translation (spread_radius) and allowed ligand rotation (XYZ_Range).
The allowed ligand translation variable sets how far from the initial centroid coordinates
the calculation is allowed to move the molecule (in Angstroms), while the ligand rotation
variable allows for control of the rotation range (in radians) in the calculation.

EGAD General Energy Function
During computational redesign, each variant is scored by the EGAD energy function.
EGAD’s energy function is a linear combination of the calculated energy of the statically
held backbone atoms ("Gi_bkbn), the energy of the particular rotamer at position i
(%Gi_internal) and the pairwise interaction of rotamers at positions i and j (
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!!! !!!"! ).

Each portion (ie each term) of the equation is further expanded to the vacuum energy and
solvation energy components. The vacuum energy consists of the VdW, Coulombic,
Torsional correction terms, while the solvation energy consists of Generalized Born
calculation.
(Note: %G is the modified Gibbs free energy equation, while the E represents a free
energy approximation, as the entropy term has been omitted in the calculation.)
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Figure 31: van der Waals, Coulombic electrostatic potentials and torsional potential

It is worthy to note that bond stretching and angle bending terms are not taken into
account in this calculation, because the model assumes a rigid backbone and uses
idealized rotamer conformations. To reduce computational overhead, long range
interactions (greater than 10Å) are ignored. Dielectric constants were chosen empirically
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to a value of 8.0. Again, we have atoms i and j , with !!" , with charge !! , being the radial
distance between the two, and !!"! ! !!" ! !!!! being their dihedral angle, VdW equilibrium
distance and well depth respectively. Lastly, in the torsional potential term there is a !!!"
term which represents the Fourier series coefficients for torsional energies.
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Figure 32:Generalized Born model used in EGAD

In the equation above, the Born radii are calculated from the supplied protein structure.
Where !! is Coulomb’s constant, i and j are the atoms, with r being the distance between
said atoms. We take into account two dielectric constants, that of the molecule (!! ), and
that of the surrounding solvent (!! ), along with the individual charge of each atom i (!! )
with a Born radius of !! . The screening interactions are described by !!" .
The energy terms only apply to the protein, and not to the small molecule, the small
molecule is a rigid structure, whose conformation was determined by energy
minimization using in vacuo ab initio methods, specifically the 6-31+g basis set of the
restricted Hartree-Fock calculation by Gaussian 03121.
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EGAD Efficiency
EGAD’s efficiency stems from the architecture of the calculation. The energies of all the
possible combinations of rotamers and mutants for the selected amino acids are
calculated and stored. The precalculation of energies, though space inefficient, allows for
rapid energy lookup.
The low energy search algorithm employed by EGAD in our experiments uses a
stochastic approach found in Monte Carlo simulations. The Monte Carlo search allows
us to sample rapidly a large energy landscape that has been parameterized in the previous
tabling step. Monte Carlo methods sample the local energy space until a local minimum
is found, and with large number of attempts, this local minimum is assumed to be the
global energy minimum. Dead end elimination has also been implemented in the energy
minimizer, though its use is limited to initial pruning prior to Monte Carlo minimization.
The greatest limitation is the necessity to maintain rigidity of the backbone atoms during
the calculation. Because of the complexity of including backbone flexibility in the
calculation, certain restrictions and compromises must be made to make the calculation
feasible. The van der Waals radius scaling factor, is variable between 90% and 95%, to
account for small backbone rearrangements.

SURFNET
The torrent of data following an EGAD run is difficult to parse without context. In a
typical calculation, between five and 100 output structures can be generated, each with a
different final energy and amino acid composition at the variable sites. The minor energy
variations between each solution are not necessarily meaningful, as composite
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assumptions within the calculation lead to large error bars. Thus a secondary screening
methodology is required to further determine the best result.
To create the best binding cavity for the small molecule, additional space surround it
must be minimized. As a secondary screen, the output from EGAD is processed via
SURFNET123 which generates molecular surfaces of molecules, and can find voids
between the protein and the small molecule. SURFNET is freely available online
(http://www.ebi.ac.uk/thornton-srv/software/SURFNET/) to academic institutions, and
has been installed on the lab linux workstation Solitude. SURFNET processes a single
output file individually, as determined by the input parameter file associated with
SURFNET (surfnet.par), and outputs a series of files that contain geometric information
of the voids between the protein and ligand, among others. SURFNET has other
functions such as cleft detection, and numerous geometric rendering options, however
these are beyond the scope of this thesis.

Running EGAD & SURFNET
EGAD runs are composed of a series of terminal commands, and can be easily batched
together. For data separation simplicity, each run of EGAD performed is within a
serialized directory structure. For instance, the directory doxdes3.2.11 indicates a design
run using the doxycycline ligand, third generation of major design principals, second set
of experiments, 11th variant on input parameters. This directory structure is meant as a
guide for simplification of data analysis, and specifics are likely to change from run to
run. Each directory (and therefore individual run) requires the following files.
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common_inputs directory
This directory contains the rotamer libraries, Van der Waals residue parameters,
torsional parameters and atom specific information as part of the Van der Waals radii for
the OPLS forcefield, and test points for the SASA calculation. As this directory may be
modified between runs, it is useful to reference a local copy within the directory structure
for each run. These files are called by the protein input file component of the EGAD
setup.
etable.cmdline
Etable.cmdline contains the flags for EGAD that specify the protein input files, the ligand
input file, and whether WT residues are allowed.

Figure 33: etable.cmdline

In this example, the EGAD protein input files are called by 1SHJ_A&B.input, the ligand
file is called by dox.liginput, and WT residues and rotamers are implicitly allowed.
1SHJ_A.input
For this example, we are using separate protein files for each side of the dimer to allow
each side to be addressed and varied independently. The first file called contains calls to
files and parameters for the protein component of the run. The critical flag of the file,
TEMPLATE_PDB refers to the location of the PDB input file. This file should be in the
directory of each run, and in this example, specifies the A chain of 1SHJ.pdb
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Figure 34: Protein component input parameters
The first file loaded by etable.cmdline contains protein component input parameters such as the
location of the PDB that stores the geometric coordinates (TEMPLATE_PDB), and the variable
positions within that PDB.

The VARIABLE_POSITIONS flag refers to the residues that are specified for
computation. In the example (Figure 34), only residue at position 223 is included, forced
into tyrosine (TYR), and only with rotameric freedom. This calculation will allow the
ligand to move, position 223 to sample rotamers, with the remaining residues held fixed.
If a specific mutation is called for, or only specific residues allowed, the allowed residues
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can be listed in comma delimited format. The flag ‘all’ will allow any residue type,
except glycine, cysteine and proline (Figure 35).

Figure 35: Variable positions in EGAD
Variable positions explicitly called by the protein parameter input file. Positions not listed are
modeled as listed by the PDB geometric coordinates, but not varied, nor allowed to move.

Notations after hash (#) are ignored by EGAD, and can be used as comments for the user.
The 1SHJ_B.input file only contains the location of the B PDB, and variable positions in
that PDB.
Machinefile
This file is only called when running in an MPI parallel processing cluster
environment124, and contains machine names on which to run. All EGAD simulations to
date have been run on either the generously provided Handel pandemonium cluster at
UCSD or the compbio cluster at the University of Massachusetts, Amherst.
Dox.liginput
The contents of this file refer to the ligand parameter file, and also mark the initialization
coordinates for the ligand. Under the location flag, the coordinates listed are the center of
the ligand, and can be calculated by averaging the X Y and Z components separately
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from the ligand parameter file. The Spread Radius refers to the distance in Angstroms
the ligand moves from the initial location, while the grain is the number of steps the
ligand will make in each axis. The rotation and range flags indicate the number of
rotations to make about each axis, and the range, in radians, which rotations should be
made.
Dox.ligparm
The ligand parameterization is contained within this file. In this specific example, the file
contains necessary information to define doxycycline. Layout of this file is reminiscent to
a PDB file, in that the file is in a space-delimited format. Column 1 contains the flag for
coordinates, followed by atom number, atom identity, then atom type. The atom type is
for the OPLS forcefield and needs to be determined by finding the closest atom type in
the forcefield file that describes that atoms chemical situation. The column composed
primarily of 0’s refers to the rigidness of that atom relative to other atoms connected to it.
Following this column are three columns of X Y and Z coordinates that allow atom
distance information to be calculated. The final column is the charge associated with the
atom, and this information is taken from an ab initio energy minimization calculation. It
is important to note that to move the ligand to a new staring position requires that new
coordinates be entered into this file, and a new center of coordinates be calculated.
tabling.sc
This script file builds the master tabling input file from components outline above and
starts the program called MPIPolymerTable, with the output file being generated in the
root directory of the script starting location.
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Figure 36: tabling.sc start script
Tabling initiation script that ensures the proper syntax of a MPI distributed computing run to be
executed using the etable.cmdline and machinefile files as inputs, while generating a log file
(etable.log) in the same directory.

Stopping this script with the escape character during tabling will not stop the tabling run,
only halt printing of the tabling log file. To stop tabling, the job must be killed by PMID
in the linux process manager on each machine (node) running the tabling. Running two
simultaneous tabling jobs in the same directory can lead to corrupted output files, and is
generally bad practice. Depending on the input parameters, job size, and available
computing power, tabling can take between 6-12 hours. Though the whole set is
ostensibly parallelizable, the single most computationally intensive segment is the ligand
parameterization, which cannot be spread between machines. It is therefore
recommended that tabling be undertaken on one machine. Output files generated end in
the file extensions .etable and .groups.
Monte_carlo.cmdline
Once tabling is completed, search for the minimum energy value can be done using the
MonteCarlo program of EGAD. The random seed is an important variable, and must be
changed between each run of the same input to ensure MonteCarlo produces independent
results (Figure 37). The number of runs, saved and number of steps is self explanatory, as
these parameters determine the length of the random walk, and the number of top
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solutions to be saved. The penultimate flags in this file refer to the output files from
tabling. These files should reside in the same directory as the MonteCarlo run, and so file
paths are unnecessary. The final flag in the input file refers to the number of
DeadEndElimination steps to take. This flag is optional.

Figure 37: monte_carlo.cmdline
The monte_carlo.cmdline file houses pointers to the tabling output files (etable and groups) and
specifies the number of runs, how many of those runs are saved, and how many steps per run are to
be in each Monte_Carlo run. Eliminate 2 refers to the rounds of DEE prior to the start of
Monte_Carlo.

montecarlo.sc
The montecarlo.sc script is very similar to tableing.sc (Figure 36), in that it invokes the
MonteCarlo program with the proper input files listed (Figure 38).

Figure 38: montecarlo.sc start script
Similar to the tabling script, this script initiates the minimizer step of EGAD while in a MPI
controlled multi node environment.

Struct.sc
The output file from the MonteCarlo program (monte_carlo.log) contains references to
the atomic positions that represent the minimum for the run. The script
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print_structuresnue.py is a python script whose input syntax takes the monte_carlo.log
file, the protein file and the ligand file to generate PDBs of final output structures.
Struct.sc calls print_structuresnue.py two times, to generate SASA volumes for the
protein with and without the ligand in the final conformation present. This feature has
been primarily deprecated due to the more accurate SURFNET being employed, though
the additional information from a SASA water roll is useful in some instances where the
ligand is protruding from the allosteric pocket.
PRESURF.sc
The SURFNET program is run after PDB model generation. Modification of the
surfnet.par file is required to specify the number of atoms within the protein and the
ligand. SURFNET then calculates the volume between the two bodies using spheres
between 1.0Å and 4.0Å. The additional options afforded by SURFNET are beyond the
scope of this thesis, and can be best referenced at the SURFNET website. The presurf
script generates a new directory, surfout, where the outputs from the SURFNET run are
subsequently written. Presurf.sc removes all previous run outputs generated by
SURFNET prior to starting a new SURFNET calculation.
A successful SURFNET calculation will yield many output files, but the critical files for
EGAD ligand/protein spacing analysis are surfnet.pdb and volumes.pdb. Simple
visualization of the remaining space surrounding the ligand can be accomplished by
loading the output PDB from EGAD into a molecular viewer such as PyMol along with
surfnet.pdb. This will generate two sets of MAP points, one corresponding to the small
molecule, the second corresponding to the surrounding space.
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Figure 39: SURFNET output displayed in PyMol
An output solution from EGAD and SURFNET rendered in PyMol. The extra space (cyan spheres)
surrounds the ligand (green spheres). Hydrogens not seen in the crystal structure have been added
where chemically prudent.

To quantify the volume remaining in the cavity, a simple calculation must be done with
figures from volumes.pdb. During the SURFNET calculation, SURFNET calculates the
total volume of the ligand+protein, protein only and ligand only. Remaining volume of
the cavity is calculated by subtracting the ligand volume from the total volume of the
complex, then subtracting the result from the volume of the protein only.

Initial EGAD Designs using Tetracycline
Initial EGAD designs were undertaken in a close collaboration with Dr. Arnab Chowdry
and Dr. Tracy Handel of UCSD. Tetracycline was chosen as a ligand design target at that
time, as an energy-minimized structure for doxycycline was not yet available.
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Residues selected for inclusion in the first round of design were chosen for their
proximity and potential interaction with the tetracycline (Figure 40 A, Table 6).
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Figure 40: Des1.0 binding ligand interaction pocket
(A) The native interaction pocket with residues included in design (green) labeled. Tetracycline
(orange) is in the conformation predicted by EGAD. (B) Des1.0, the designed output from EGAD.
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Table 6: Design results for Des1.0 at mutated positions

As mentioned in chapter 1, the free rotomeric freedom of the tyrosine at 223 is critical for
activity. As such, the results from the first design were troubling in that the adjacent
residue to the allosteric switch tyrosine 223 was a tryptophan. The bulkiness of the
resultant residue, while beneficial to the overall design, posed a potential problem if the
tryptophan restricted the movement of tyrosine 223. As a first step, the single point
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mutant F221W was generated (Figure 41 A) and its activity measured relative to wild
type enzyme (Figure 41 B). No appreciable difference was noted in both expression of
the F221W variant, nor in the activity.
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Figure 41: Expression and validation of F221W & Des1.0
Expression and activity validation results for the intermediate design mutant (F221W) and the full
first generation design (Des1.0). The expression of F221W yielded a protein with expected
molecular weights (A), and activity recorded was comparable to WT (B). The full mutant design,
(Des1.0) showed significantly decreased activity relative to WT (B), but behaved just as WT in a
gel assay.

The positive result with F221W led to the generation and expression of the full design
mutant. However, the EGAD computation resulted in an asymmetric design, which due
to limitations of current caspase-7 expression systems, was not available. Caspase-7,
being a obligate homodimer would require the generation of two independently
mutateable monomers. The generation of such a expression system construct was
undertaken, the project remains unfinished. This technical problem required the
generation of a design that would be symmetrical about the allosteric cavity.
Conveniently, the EGAD solution was nearly symmetrical on both sides of the dimer,
with only position 211 varying. Upon examination of the computational result, it was
decided that a methionine would be beneficial to include on both sides of the dimer, as
93

opposed to mutation to an alanine. The position of residue 211 near the N-terminus of the
L2’ loop is considered mobile, as the L2’ loop necessarily requires rearrangement during
the substrate binding groove formation (Figure 6).
The full design (Des1.0) was expressed, purified (Figure 41), and assayed against WT to
assess relative activity. Though the expression of Des1.0 resulted in a protein that
behaved like WT in both purification and gel assay, the catalytic activity was severely
impaired (15-fold reduced) relative to WT. However since Des1.0 was still a somewhat
functional caspase-7, and given that the primary goal of the design is to engineer in
sensitivity and binding for tetracycline, we tested this. To assay tetracycline-mediated
inhibition, caspase-7 and Des1.0 were subjected to tetracycline to determine IC50
irrespective of the intrinsic activity (Figure 42). Des1.0 showed a 50% lower IC50 relative
to WT, demonstrating a partial success in the computational design.

Figure 42: Caspase-7 vs Des1.0 IC50 to tetracycline
The sensitivity of Des1.0 relative to WT caspase-7 to the target tetracycline molecule is 50%
higher, suggesting a successful first round of design using EGAD.

The severely lowered caspase-7 activity of Des1.0 lead to the investigation of L2’ as a
candidate for design by alanine scanning mutagenesis (Chapter 2). It was subsequently
discovered that position I213 is of critical importance to the formation of the substrate
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binding groove, and thus both positions 213 and 212 were removed from subsequent
design initiatives.

Designs post Des1.0
The lessons learned during Des1.0 and further investigations to L2’ loop’s amenability
for mutation guided later computational designs. Because doxycycline was 1Å longer
than tetracycline, and could therefore reach between the two Y223 residues on opposite
sides of the allosteric pocket, doxycycline was used in all subsequent rounds of design.
The doxycycline structure was subjected to ab initio energy minimization in Gaussian
03121 and geometric and chemical parameters were input to the dox.ligparam file.
Additionally, residues 212 and 213 were included in the calculation, but were only
allowed rotameric freedom.
A number of variables that included Van der Waals radii scaling, random seed changes,
included residues, ligand starting position and movement were varied in numerous runs
with a total of 90 successful solutions compared. A direct comparison of similar runs, as
defined by the same residues being varied, can be made and trends from these results can
be elucidated. In set one, with 42 solutions across 14 different setups we find where
certain residues are preferred over others. For instance residue number 215 in chain A is
preferred and 89% of the time, while other residues are selected here the remaining 11%
of the time. However the preference of one residue over another is not always so
overwhelming, as residue 292 is split between methionine, alanine, and arginine in
almost equal amounts.
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The strength of the asymmetric nature of the design is evident when one compares chain
A to chain B. Using the example of residue 215, chain A differs from chain B in that
chain A, glutamate is chosen while in chain B a tryptophan residue is selected 84% of the
time. It is important to note that these consensus residue selections do not always
translate across different input parameters.
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Figure 43: Consensus residues across one set of solutions. (N=42)
Percent selection of a specific residue at each the variable design position for EGAD design series
3.2.x. Percentages are score based on number of occurrences of that residue in all solutions from
multiple runs.
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A second set of results (48 solutions from 11 separate runs) differs from set 1 in that
different residues were selected for mutation and the starting position of the small
molecule was also changed. The reproducibility of EGAD as a design tool becomes
evident when one compares two starting positions of the small molecule and the resulting
consensus residues predicted by the computation. For instance, at residue 215 in chain A,
the predicted consensus residue is a glutamate, while in the second set at the same residue
position an aspartate is called for. This suggests that an acidic residue in this position is
likely to be beneficial for binding of the small molecule. Trends such as these can be
funneled into subsequent designs, such that position 215 is only allowed to vary to acidic
residues (Figure 35). Finally, after a few rounds to select for not only residue chemistry,
but also possibly residue identity, scoring based on residual space in the small molecule
cavity can be undertaken.
No computational design result can be discussed without mentioning final energies
calculated. During the minimization step, when a Monte Carlo simulation is searching for
the lowest set of pairwise energies, EGAD uses a force field calculation in hartrees to
score outputs. However, due to the variances and inherent approximations within such a
calculation, comparison of the direct energy values between runs is not recommended.
Generally speaking, output energies are on the order of -1900 to -2300 depending on
factors such as Wan der Waal radii and final position of the small molecule are typical
from an EGAD calculation. Higher energies, especially if positive, suggest steric
clashing, which we could observe post-run.
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Figure 44: Consensus residues across one set of solutions. (N=48)
Second set of solutions (3.3.x series) based on a greater number of positions varied and a new
starting position for the small molecule.

The remaining space surrounding the small molecule in each design varies based on the
final ligand position, and the surrounding residues predicted. Selection of protein
designs to carry forward for expression in E. coli must be made not simply based on
consensus residues at specific positions but also their contribution to a smaller binding
pocket. In the case that a residue does not fall into a consensus, the secondary screening
for unfilled cavity volume using SURFNET will allow further refinement and selection of
residues for mutation.
Using tools like those outlined above can greatly simplify the selection of mutants to test
experimentally. Experimental validation of these designs has not been attempted due to
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the inability to express and purify a heterodimeric version of caspase-7. Development of
a heterodimeric caspase-7 has been undertaken by another graduate student in the lab.
The results of the calculations presented here, along with source code for EGAD and the
scripts which automate the computation can be found in the /home/shared/EGAD
directory on the Hardy linux workstation, solitude. As of the writing of this thesis,
EGAD has fallen into disrepair and is not currently accessible on either the UCSD cluster
or the compbio cluster. Installation and compilation of EGAD from source is possible,
though directions for this task are beyond the scope of this thesis. SURFNET has been
installed on the Hardy solitude linux workstation, and can be invoked using the command
SURFNET in the directory in which the proper input files are located.
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CHAPTER V

CONCLUSION
Caspase-7 is an excellent system to study, as the wealth of knowledge that has been
gleaned in this work from the investigation of its loop movement, active site
conformation, and allosteric control can be generalized as a model system for the study of
other caspases, and even proteases in general. The outwardly unique characteristics found
in caspase-7 have analogs within the protease family, and work on other proteins can be
improved based on the findings presented in this thesis.
Loop or structural rearrangement upon binding of substrates or co-factors is not unique to
caspases. The classical example is hemoglobin, where a tetramer undergoes a global
conformation rearrangement as a function of binding oxygen125. In this example, there is
a large conformational rearrangement change upon binding oxygen that has become a
hallmark of the protein. Other systems have large conformational changes in their life
cycle, such as HIV protease, whose flaps open and close depending on binding state126, or
influenza hemagglutinin, which seems to adopt a ‘spring loaded’ injection mechanism
during its function127. All these structural rearrangements are required for the protein to
function. In caspases, there is an intersubunit cleavage that is required for activation,
implying that either the conformation of the zymogen is not sufficiently flexible to
undergo catalysis, or that a structural rearrangement is necessary. The best metaphor for
an executioner caspase is an unloaded pistol. Evolution has designed multiple fail-safes
to ensure that caspases do not inadvertently activate. In our metaphor, the zymogen
caspase is an unloaded pistol, ready to accept the ammunition. When cleaved to the
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mature form, caspases become loaded, ready to fire, but like a pistol, require that
additional steps be taken to make the mechanism run. This is analogous to the mature
state of caspases, where the loops are almost ready, but not in a catalytically competent
conformation. The multiple steps involved, along with the placement of the loops ensure
that caspases are not inadvertently initiated, a process which would be very detrimental to
a cell.
Because of this large rearrangement of loops that compose the active site, the active site
is naturally more flexible than the core of the protein. At first blush, the inherent
flexibility of an active site can be more of a hindrance than a benefit for a protein as
critical for cell homeostasis as a caspase. It is generally agreed that catalytic sites occur at
the interfaces of domains or intersubunits128, however, catalysis of reactions by proteins
requires very specific orientation of the residues involved. The additional support
afforded by the surrounding structures in proteins at interfaces can rigidify the active site
to allow for proper geometry to undergo catalysis. Additionally, an interface can present
a solvent accessible region for the interaction of substrate and enzyme, facilitating the
capture of substrate and release of product. In the case of HIV-1 protease, the dimer
interface houses the catalytic residues which remain stationary, while two ‘flaps’ undergo
conformation changes that move 7Å during substrate binding129,130. This relative burial of
the active site as compared to caspases does not affect the enzyme efficiency. HIV-1
protease exhibits a higher turnover of 42.3 s-1 while caspases in general exhibit much
slower turnover on the order of 1 s-1, even though the active site is much more exposed.
However, the Km of the buried active site in HIV-1 is much lower (3.7 µM) as compared
to caspases, which have Km constants on the order of 60-100 µM. One might assume that
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the protein with more flexible loops would have a lower Km, as the active site binding
groove is more flexible and thus less likely to hold substrate. However as we see in this
example, this is not the case. The high Km may be related to the necessity for higher
specificity in caspases, combined with the rearrangement of the loops between at least
two states in solution.
The discovery of the two distinct caspase-7 states in solution, as described earlier in the
pistol metaphor, has wide ranging implications for the further use of caspases. Because
the global folds of caspases are so similar, this lends credence to the idea that the two
state nature of caspase-7 is not unique among caspases. Along these lines, the large
thermal stability increase noted in caspases, in particular caspase-7, can be used in drug
design efforts not currently being undertaken. Using methods like thermo sensitive dyes
to detect thermal denaturation is established, and has been used in high throughput
applications for drug discovery131. This method relies on a difference in Tm upon the
binding of ligand to differentiate specific and non-specific binders. The noted changes in
thermal stability upon binding of ligand vary in caspases. For instance, caspase-7 and
caspase-9 share the highest known difference between bound and unbound states of 17
degrees (Caspase-9 thermal melt data generously provided by Kristen Huber,
unpublished). This is compared to caspase-3 which has a Tm of greater than 7 degrees,
and -6, which has a %Tm of only 3 degrees27. The low %Tm for caspase-6 has can be
explained in the appearance of an extended helix that preselects caspase-6 to a more
active state, however the lower %Tm for caspase-3 relative to caspase-7 is likely due to the
inability to measure melting temperatures above 90 degrees on the CD spectrometer used.
The similar structures of other caspases suggest that a one would find increase of stability
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on the order of 17 degrees upon binding substrate. The energy associated with binding
and stabilization on this scale is not trivial. This stabilization in caspases can be
compared to the binding of biotin to streptavidin, an incredibly tight interaction, which
results in a thermal stabilization of 37 degrees in Tm 132. In the interaction of streptavidin
to biotin130, the strong binding of the biotin to the hydrogen bonding network, Van der
Waals surface burial and high shape complementarity all contribute to the strength of this
non-covalent interaction.
In the thermal denaturation studies of caspases to date, a covalent inhibitor has been
present in the active site. The covalent nature of this interaction could affect the final
active site binding groove arrangement, as these loops could relax and adopt a low energy
state that is not necessarily biologically relevant. However, recent studies have shown
that the structure of caspase-7 in the presence of a non-covalently bound inhibitor adopts
a nearly identical conformation to that of the covalent inhibitor (structural information
provided by Scott Eron, unpublished data). This strongly suggests that not only are the
peptide-protein contacts sufficient to maintain caspase-7 in an active state, but that the
covalent bond at the catalytic cysteine to the inhibitor is not the driving force behind the
formation of the active site, but instead the peptide recognition is. From this, we expect
that all caspases, when interacting with the target substrate during a recognition period,
would adopt a conformation that is significantly stabilized. Thus, the native disulfide we
observe in caspase-7 could be stabilizing a non-ideal substrate recognition motif in
caspase-7, allowing the substrate to bind non-ideally, but still in a regime that allows for
proteolysis.
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Designing an inhibitor that targets the loop arrangement and not simply the binding
pocket65, interrupting the formation of the loop bundle buttress can be an effective
method for additional caspase control particularly when the loops can be accessed from
outside the substrate binding groove. Furthermore, the use of FRET as a measuring
tool133 with labeled residues on L2 and L2’ or hydrogen-deuterium exchange would give
additional insight to dynamic loop movement in solution not necessarily present in
circular dichroism data alone. Structural information can significantly improve the ability
to determine the importance of potential disulfide bridges. Stabilization of a particular
conformation is a very common method of protein regulation or even activation. In the
classic example of chymotrypsinogen, a pair of disulfide bridges stabilizes the active
form of the enzyme after the cleavage of residues that active the protein. Design of a
redox-controlled protein necessarily relies on the protein adopting a different
conformation than the active, this can be done as in caspase-7 where the structure of a
known inactive state exists. In the design of a of a redox controlled lysozyme, where only
the active conformation was known, Matthews and colleagues engineered in a disulfide
that deactivates the protein in the presence of a oxidizing environment134. The inherent
flexibility of T4 lysozyme allowed the formation of a disulfide bridge that disabled the
enzyme by locking the two lobes of the protein together. In our design of a redoxcontrolled caspase, we used a known structure of caspase-7 in the allosterically inhibited
form as a starting point. In the case of caspase-3, the lack of structural information of a
L2’ loop down conformation precluded the initial structural study of a redox loop locked
conformation, even when the native sequence of caspase-3 contains a homologous
potential disulfide to R210C in caspase-7. We postulate that because of the structural
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similarities within caspases, the design of redox loop locked caspases is not limited to
caspases of which we have structures of multiple conformations such as caspase-7.
Therefore, the application of a loop lock as we have designed can be integrated into not
only caspase-3 and -7, but also into other caspases, which would be eminently useful to
allosterically control. As has been previously shown135,136,109,137, delivery of active
proteins into cells is possible. The possibility of delivering a functional caspase into cells
with down regulated apoptosis using the redox-controlled method would allow direct and
controlled initiation of apoptosis. Delivering caspases directly to where they are needed
would be of great benefit for targeted cancer treatments, as minimization of off target
effects would limit damage to surrounding tissue.
Additionally, the capability to lock the loops over the caspase allosteric site allows less
than optimal designs from computational binding site design to be studied
crystallographically in the presence of the inhibitor. For instance, if the inhibitor has poor
binding affinity for the new designed allosteric site, a designed caspase can be incubated
in the presence of the non-covalent effector molecule in reducing conditions. The small
molecule can then be ‘trapped’ by the locking of the L2’ loops over the allosteric cavity
simply by the transference of the protein into an oxidizing environment.
A design method of using computational protein redesign can be combined with methods
currently underway in the Hardy lab, where specificity for substrate or allosteric sites are
being altered. Using EGAD design techniques along with existing mutants and their
effect on specificity, fewer new designs may have to be tested in the lab. Similarly,
EGAD designs can be improved by the use of real specificity data being collected in the
lab.
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Data from the studies discussed in this thesis can be applied generally to other systems as
demonstrated and discussed. The importance of the large rearrangement of the loop
bundle during catalysis as discussed in chapter 2 has implications not only for
computational redesign of the allosteric cavity (Chapter 4), and the design for redox
control of caspase-7 (Chapter 3), but on designs of caspase specific inhibitors and further
studies into the dynamics of caspases. To design inhibitors for a protein with large
dynamic rearrangements, taking into account the loop rearrangement can be
advantageous, as foreknowledge of sites not amenable to mutation, such as I213 on L2’,
one can target it specifically.
A direct application of the knowledge from the study of L2’ is a design of a redox
activatable caspase-7 that makes proteins eminently more drug like, as these designed
proteins can be delivered to systems with down regulated apoptosis (Chapter 3).
The strength of the toolset lies in the execution, as EGAD demonstrates by utilizing the
vast and inexpensive computational power available to test and therefore design a novel
binding site that can function as an allosteric effector. The combination of a large
sampling size of potential variants on the order of 1024 with multi-factored scoring
(Chapter 4) can significantly decrease the wet lab experimental workload. Combined with
the approaches outlined above, a new allosteric binding site can be engineered
successfully.
It is the hope of the author that future investigators apply the lessons learned and data
gathered to improve the impact of their experiments and science as a whole.
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APPENDICIES
A. CASPASE-7 IN THE PRESENCE OF AN UNCLEAVABLE PEPTIDE

Abstract
The ability to design individual caspase specific inhibitors is hindered by the shared
specificity of the executioner caspases. However, it is clear from numerous studies that
the in vivo targets of the executioner caspases vary. Thus, the understanding of the
substrate-binding groove, and by extension substrate binding and proteolysis in
particular, relies heavily on accurate atomic positioning of the catalytic residues. In this
work we present a new approach to study protein function and geometry in the presence
of an uncleavable substrate mimic, DEVD|GK. Crystallographic and binding evidence in
the presence of DEVD|GK suggests an unexpected binding mode and overall caspase-7
conformation not compatible with the canonical caspase-7 substrate-binding models,
which all rely on covalent modification of the active-site cysteine by an electrophilic
warhead on a peptide-derived inhibitor.

Introduction
Structures of caspase-7 have been solved numerous times in the presence of a covalently
bound substrate in the active site37,61,88. However, in each of these structures with the
catalytic cysteine bound to the peptide, the geometry of the cysteine-histidine dyad
(C186, H144) is incompatible with catalysis. In every case, the cysteine’s gamma sulfur
is at minimum 5Å from the histidine nitrogen. Similarly, in previously reported structures
of caspase-7 with nothing bound to the active site39, the dyad is not in a catalytic
orientation, being 4Å to 6Å apart. At the time this project was undertaken,
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crystallographic data from the R210C/C246S caspase-7 variant was not yet obtained, and
a structure of caspase-7 in the absence of an inhibitor but in a catalytic orientation was
not available.
To best determine the catalytic geometry of caspase-7 during catalysis, a structure of
caspase-7 bound to an uncleavable substrate was desired. All commercially available
active site inhibitors only included residues on the N-terminal side of the cleavage, so no
information is available about binding of amino acids on the prime side of the binding
groove. It was decided that introducing an uncleavable modified peptide bond between
the naturally occurring cleavage site C-terminal to the aspartate and a subsequent residue
would encourage substrate binding using the intrinsic binding sequence (DEVD) but
disallow peptide bond cleavage and thus substrate release. Though caspase-3 and
caspase-7 specificity has been extensively probed138,139 it has been conclusively shown
that both proteins share a canonical recognition sequence (DEVD). Recent proteome
wide substrate analysis of caspase-3 and caspase-7 show differences in P1’ and P2’
recognition sites. The potential additional benefit of mapping the P1’ and P2’ sites
encouraged the use of a substrate sequence specific to caspase-7140. A sequence of DEVD
linked by an uncleavable modified peptide bond to GK was selected for synthesis and
analysis.
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Figure 45: The uncleavable caspase-7 peptide DEVD|GK.
A caspase-7 specific uncleavable peptide consisting of DEVD followed by a modified peptide bond
lacking the carbonyl oxygen (red circle) links residues GK.

The synthesis and chemical characterization of DEVD|GK was undertaken by Dr.
Sumana Ghosh. Details can be found in the materials and methods of this chapter.

Results
Crystal structure of Caspase-7 with DEVD|GK
After synthesis and characterization, the uncleavable peptide DEVD|GK was cocrystallized with caspase-7 WT protein, and three independent data sets were obtained
and solved. As the structure of caspase-7 with DEVD|GK was suspected to be most
similar to the structure of caspase-7 in the presence of a covalently bound inhibitor, the
model for molecular replacement was 1F1J with loops removed to minimize bias in the
loops region. Initial observations of the maps from the molecular replacement solution
suggested strongly that a new caspase-7 structure had been observed. When overlaid with
1F1J, density for the loops L2, L3, and L4 were not in an identical conformation or not
visible in density entirely. This fact was particularly surprising as all existing structures
with substrate bound to the active site had nearly identical loop structures. Even in a
structure of caspase-7 with severely impaired activity (see Chapter 2), the loops adopt a
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conformation nearly identical to that of WT. Other minor changes across the whole
protein were observed during rebuilding.
Only one active site of C7 + DEVD|GK is ordered in the crystal structure. During
rebuilding, repeated attempts were made to build in loops near the active site of chain A
(one half of the dimer, composed of a large and small subunit), however, this was met
with difficulty, as the density remained ambiguous and discontinuous. In contrast, the B
chain of the protein not only had better density for the active site loops, but also
contained density consistent with the binding of DEVD|GK in a similar motif to the
binding of DEVD in 1F1J.

C186

A

B
Figure 46: Active site and DEVD visible in one half of dimer
Density for the active site cysteine is only present on one side of the dimer (chain B). (A) Density
for the uncleavable peptide is visible for residues DEV (magenta), but is discontinuous and
ambiguous further. (B) The uncleavable peptide (magenta) adopts a conformation that is related to,
but not identical to the active site bound peptide in 1F1J (cyan).

Attempts to improve density throughout the protein, non-crystallographic symmetry
(NCS) across the whole dimer was applied to a refinement step. After this containment
was applied, overall refinement statistics did not improve, rather got worse, suggesting
that the two halves of the protein could not be treated identically. NCS was successfully
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applied to improve refinement statistics in regions of caspase-7 that did not vary from
each side. Specifically, the "-sheet regions that form the core of caspases were used.
Residues 66-73, 136-141, 176-186, and 218-233 held with tight restraints at the backbone
position and medium restraint for the side chains.

Disulfide visible on one side of caspase-7 dimer
Although the binding of the peptide at the active site is somewhat ambiguous, the
discovery of disulfide bond formation at residues C100 and C246, between the large and
small subunits (Figure 19, Chapter 3) is of great interest. Intriguingly, this disulfide was
only visible on one side of the dimer, opposite of the side that showed good density for
the active site. A map generated with the residues C100 and C246 omitted shows clear
and unambiguous contiguous density consistent with a disulfide formation (Figure 47 A).
However, the same is not the case on the opposite side of the dimer, where the density for
disulfide formation is not evident (Figure 47 B).

A

B
Figure 47: Native C100-C246 disulfide visible in omit map
The formed disulfide is clearly visible on one side of the dimer in a map generated with residues
C100 and C246 omitted. (A) Both the Fo-Fc density (green, 3) contouring) and 2Fo-Fc (blue, 1)
contouring) is continuous at the site of the omitted C100-C246. (B) On the opposite side of the
dimer, the density rendered identically is discontinuous, and does not show evidence of disulfide
formation.
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We confirmed these results in three independent data sets, each collected on an
independent crystal.

C7 + DEVD|GK

Data Set 1

Data Set 2

Data Set 3

Diffraction Data
Wavelength (Å)
Resolution Range (Å)
Measured reflection
Unique reflections
Completeness (%)
Redundancy
<I/!I>
Space Group
a = b (Å)
c (Å)
# = " (°)
' (°)
rsym

1.00
50-2.75
245450
23376
99.9 (100)
10.5 (10.6)
38.9 (2.1)
P3221
90.028
185.261
90
120
7.3 (99.7)

1.00
50-2.80
298058
22243
100 (100)
13.4 (13.4)
36.0 (2.1)
P3221
90.014
185.645
90
120
10.4 (89.0)

1.00
50-2.9
82617
19670
99.4 (99.7)
4.2 (4.2)
24.6 (2.2)
P3221
90.016
185.702
90
120
8.2 (55.6)

Refinement Statistics
Atoms
Water molecules
Rwork (%)
Rfree (%)
RMSD bond length (Å)
RMSD bond angle (°)
Average B-factor (Å2)

3486
25
29.6
23.2
0.021
2.15
58.3

Table 7: Crystallographic statistics for three independent datasets of caspase-7 with DEVD|GK
Data sets are stored on the Hardy linux workstation, solitude, in the /home/xray_data/X25 Aug
2010/px10-0295 directory. Data set 1 is stored in the subdirectory /W2_UK_3/5 Data set 2 in
/C7_DEVDGK_1_8/ and Data set 3 in /C7_DEVDGK_2_1/

Inhibition of caspase-7 using DEVD and DEVD|GK
In light of the unusual structural results of caspase-7 co-crystallized with DEVD|GK,
binding of DEVD|GK vs DEVD was compared. To asses whether DEVD|GK binds in
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similar fashion to the native recognition sequence of DEVD, DEVD|GK’s inhibition was
compared to the peptide DEVD. It was expected that the recognition sequence of
DEVD|GK would be sufficiently similar to that of DEVD, causing the inhibition to be
similar to product inhibition, and be competitive.

0.3

0.3

0uM DEVD
200uM DEVD
400uM DEVD
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0.0
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200
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Figure 48: Inhibition curves based on substrate titration
The inhibition titration curves of DEVD (A) vs DEVD|GK (B) measured during a substrate titration
using DEVD-AMC as substrate with protein concentrations of 250 nM for DEVD 175 nM for
DEVD|GK.

kcat
Km

DEVD
217.2
65.3

0 µM
DEVD|GK
225.2
45.93

DEVD
73.9
95.86

200 µM
DEVD|GK
179.6
47.8

DEVD
36.0
235.1

400 µM
DEVD|GK
150.0
46.04

Table 8: Kinetic parameters of caspase-7 in the presence of DEVD and DEVD|GK.
Kinetic parameters are fit from data in Figure 48.
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Discussion
The surprising results from the crystal structure, and the unexpected inhibition results
suggest a different binding mode for the un-cleavable peptide. In the crystal structure, the
peptide is visible to the P2 position, however the density becomes ambiguous and noncontiguous making the placement of the P1 aspartate impossible. Similarly, the P1 pocket
is occupied by the catalytic cysteine where in the 1F1J structure the P1 aspartate finds the
P1 site (Figure 46). Then minor but significant differences between the 1F1J structure
and the structure with the un-cleavable peptide around the active site suggest that
DEVD|GK does not bind in the canonically understood fashion.
It is also significant that there are obvious differences between the two halves of the
dimer. While the uncleavable peptide can be resolved on one half of the dimer, the
opposite side of the dimer is much more disordered. The region surrounding the active
site in chain A is missing many more residues. Specifically, the catalytic cysteine in chain
A is not visible nor is the uncleavable peptide.
This asymmetry is carried forward in the region of the C100-C246 disulfide.
Interestingly, the disulfide is visible only on the side of the dimer where the active site is
disordered. On the side of the diner where peptide is visible, the disulfide is clearly not
formed (Figure 47). The cause of this asymmetry may be related to the unexpected
binding mode of the uncleavable peptide. The uncleavable peptide is not acting like a
competitive inhibitor to the fluorescent substrate, rather it is only affecting the kcat, while
leaving KM unaffected thus exhibiting classic noncompetitive inhibition properties. On
the other hand, the control DEVD peptide, is exhibiting mixed inhibition in that both KM
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and kcat are being affected. It is therefore difficult to conclude with any certainty on the
mechanism of binding or inhibition despite the solution of a crystal structure.
Although the kinetics experiments leave much to be studied, the crystallographic data is
more conducive of interpretation. The appearance of resolvable uncleavable peptide on
one half of the dimer, while a stabilizing disulfide is formed on the opposite side of the
dimer may suggest that caspase-7 can accommodate binding of substrates in odd
confirmations. The uncleavable peptide necessarily contains a non-natural peptide bond
right at the site of caspase-7 cleavage between D and G in DEVDGK. This un-cleavable
bond has sp3 geometry as opposed to the standard peptide bond sp2 geometry. One
additional conclusion that can be made from the crystallographic data is that the
treatment of caspase-7 as a set of identical monomers is not valid. The imposition of noncrystallographic symmetry during structural refinement must be made judiciously, as the
dimers appear to act independently.
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Materials and Methods
Synthesis of uncleavable bond peptide
The synthesis and characterization of the uncleavable DEVD|GK peptide was done by
Dr. Sumana Ghosh during her tenure in the Hardy Lab. Figure used with permission.

!

!

Fmoc-L-Asp-N(Me)OMe,(9H-fluoren-9-yl)methyl-(S)-1-(N-methoxy-Nmethylcarbonyl)-2 (tert-butoxycarbonyl)ethylcarbamate, (3). N-Fmoc-L-aspartic acid "tert-butyl ester (2, 2 gm, 4.86 mmol) and N,O-dimethyl hydroxylamine hydrochloride
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(0.57 gm, 5.83 mmol) were dissolved in 15 ml DMF. The reaction mixture was cooled
and DIEA (2 ml, 11.7 mmol) followed by HBTU (2.2 gm, 5.83 mmol) were added into it.
The resulting solution was allowed to stir for 5-6 h at room temperature. At end the
reaction mixture was extracted with ethylacetate and successively washed with 0.2 N
HCl, saturated NaHCO3 solution and finally with brine. The crude gummy liquid was
purified by column chromatography using 0.5 % MeOH/DCM as the eluent. The solvent
was evaporated to afford gummy liquid (3, 1.7 gm) as 80% isolated yield. 1H-NMR
(CDCl3, 400 MHz) * (ppm) 1.44 (s, 9H), 2.6 (dd, J1 = 16 Hz, J2 = 7 Hz, 1H), 2.74 (dd,
J1 = 16 Hz, J2 = 5.3 Hz, 1H), 3.2 (s, 3H), 3.8 (s, 3H), 4.23 (t, J = 7.1 Hz, 2H), 4.36 (d, J =
7.3 Hz, 2H), 5.04 (m, 1H), 5.72 (d, 1H), 7.32 (t, J = 7.4 Hz, 2H), 7.4 (t, J = 7.4 Hz, 2H),
7.6 (d, J = 7.4 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H). (Lab Note book, p. 94, 98)
(9H-fluoren-9-yl)methyl-(S)-2-(tert-butoxycarbonyl)-1-formylethylcarbamate,(4). To a
solution of Weinreb amide (3, 0.1 gm, 0.22 mmol) in 2 ml anhydrous THF, 13 mg (0.33
mmol) Lithium aluminium hydride was added at 0 oC (ice). The reaction mixture was
stirred at 0 oC for 2 h 30 min. and then quenched by addition of 10 ml 5% KHSO4
solution. The resulting solution was extracted with ethylacetate, washed 2 or 3 times with
5 % KHSO4 solution, brine and dried (MgSO4) and concentrated under reduced pressure.
The resulting aldehyde was purified by silica column chromatography eluting with DCM
and MeOH/DCM mixture. The final compound was obtained using 2-2.5 % MeOH/DCM
as eluent . The aldehyde was obtained as gummy liquid almost 70 % (0.06 gm) isolated
yield. 1H-NMR (CDCl3, 400 MHz) * (ppm) 1.45 (s, 9H), 2.78 (dd, J1 = 17.2 Hz, J2 = 4.6
Hz, 1H), 2.96 (dd, J1 = 17.2 Hz, J2 = 4.8 Hz, 1H), 4.24 (t, J = 6.8 Hz, 2H), 4.38-4.46 (m,
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3H), 5.9 (d, 1H), 7.32 (t, J = 7.4 Hz, 2H), 7.4 (t, J = 7.5 Hz, 2H), 7.6 (d, J = 7.4 Hz, 2H),
7.77 (d, J = 7.5 Hz, 2H) 9.65 (s, 1H).

(9H-fluoren-9-yl)methyl(S)-1-(((benzyloxy)carbonyl)methylamino)-3-(tertbutoxycarbonyl) propan-2-ylcarbamate, (5). Compound 4 (1.1 gm, 2.8 mmol) was
dissolved in 7 ml MeOH. Into that p-toluenesulfonate salt of Gly-OBn (1.13 gm, 3.36
mmol) along with 0.208 ml (3.64 mmol) acetic acid and some amount of molecular
sieves were added. The resultant mixture was stirred at room temperature for an hour.
Then sodium cyanoborohydride (3.36 mmol, 0.25 gm equivalent to 4 ml of 1 M
NaCNBH4 solution in THF) was added dropwise into the reaction mixture at room
temperature. Immediately a white precipitate starts forming and continued stirring at
room temperature for overnight. The resultant solution was then diluted with methanol,
filtered and evaporated. The resultant crude compound was dissolved in ethylacetate and
successively washed with water, saturated NaHCO3 solution, brine and dried over
Na2SO4. The product was purified using EtOAC/Hexane as eluent and the product was
obtained using 20% ethylacetate/hexane as eluent. 1H-NMR (CDCl3, 400 MHz) * (ppm)
1.45 (s, 9H), 2.51 (dd, 1H), 2.54 (dd, 1H), 2.76 (dd, 1H), 2.82 (dd, 1H), 3.47 (d, J = 6.0
Hz, 2H), 4.05 (m, 1H), 4.23 (t, J = 7 Hz, 2H), 4.4 (d, J = 6.6 Hz, 2H), 5.2 (s, 2H), 5.6 (d,
1H), 7.3-7.4 (m, 9H), 7.6 (d, J = 7.4 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H).
Synthesis of (6). Compound 5 (0.22 gm, 0.4 mmol) was dissolved in 10 ml anhydrous
THF followed by the addition of 14 µl (0.08 mmol) DIEA. The reaction mixture was
cooled to 0oC and BOC2O(DiBoc Anhydride) (0.096 gm, 0.44 mmol) was added
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dropwise into it. The resultant solution was stirred at room temperature for 6 h. The
solvent was evaporated and purified by silica column chromatography. The product was
obtained while eluting with 1% MeOH/DCM for an 80% (0.17 gm) isolated yield. 1HNMR (CDCl3, 400 MHz) * (ppm) 1.42 (bs, 18H), 2.47 (dd, J1 = 17.0 Hz, J2 = 6.4 Hz,
1H), 2.62 (dd, J1 = 14.0 Hz, J2 = 5.1 Hz, 1H), 3.3-3.4 (m, 1H), 3.5-3.62 (m, 1H), 3.96 (q,
J1 = 12.0 Hz, 2H), 4.03-4.05 (m, 1H), 4.2 (t, J = 7 Hz, 2H), 4.35 (dd, J1 = 25.4 Hz, J1 =
5.6 Hz, 2H), 5.2 (s, 2H), 5.6 (d, 1H), 7.3-7.4 (m, 9H), 7.6 (d, J = 7.4 Hz, 2H), 7.74 (d, J =
7.5 Hz, 2H).
Synthesis of (1). Compound 6 (1.2 gm, 1.86 mmol) was dissolved in 20 ml MeOH and
Pd/C (Paladium charcoal) (10%, 150 mg) was added into it under inert atmosphere. The
reaction mixture was stirred and hydrogenated over 2h 30 min. The resultant solution was
filtered and purified by silica column chromatography. The product was obtained while
eluting with 2% MeOH/DCM mixture. The yield of the reaction is almost 85%. 1H-NMR
(CDCl3, 400 MHz) * (ppm) 1.42 (bs, 18H), 2.45-2.5 (dd, J1 = 17.0 Hz, J2 = 6.4 Hz, 1H),
2.59-2.64 (dd, J1 = 14.0 Hz, J2 = 5.1 Hz, 1H), 3.3-3.4 (m, 1H), 3.51-3.62 (m, 1H), 3.94
(q, J1 = 18.0 Hz, 2H), 4.03-4.05 (m, 1H), 4.2 (t, J = 7 Hz, 2H), 4.35 (dd, J1 = 25.4 Hz, J1
= 7 Hz, 2H), 5.97 (d, 1H), 7.3 (t, J = 7.4 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.6 (m, 2H),
7.74 (d, J = 7.5 Hz, 1H)

Inhibition assays with DEVD and DEVD|GK
Enzyme concentrations were determined by active site titration with covalent substrate
DEVD-CHO (N-Acetyl-Asp-Glu-Val-Asp-Aldehyde, Enzo Lifesciences) in caspase
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activity buffer containing 100 mM HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) pH 7.0, 10% polyethylene glycol 400, 0.1% CHAPS, 5
mM "-mercaptoethanol, and 5 mM CaCl2 using the flourogenic substrate, DEVD-AMC
(N-acetyl-Asp-Glu-Val-Asp (7-amino-4-methylcoumarin), Enzo Lifesciences),
Ex365/Em495. Active site titration samples were incubated over a period of 2 hours in
120 mM NaCl 20 mM Tris pH 8.0 at nanomolar concentrations. Optimal labeling was
observed when protein was added to DEVD-CHO solvated in DMSO in 96-well Vbottom plates, sealed with tape, and incubated at room temperature. 22.5 µL and 90 µL
aliquots were transferred to black-well plates in duplicate, and assayed with 50-fold
molar excess of substrate. For substrate inhibition measurements, 100 nM protein was
assayed with DEVD (Biomatic Corporation) or DEVD|GK (synthesized in house by Dr.
Sumana Ghosh) present using a fluorescent substrate titration over the range of 0-1000
µM DEVD-AMC over the course of seven minutes. Data for concentrations above 1000
µM was omitted due to observed product inhibition. Assays were performed at 37°C in
25 µL and 100 µL volumes in 96 or 384 well microplate format using a Molecular
Devices Spectramax M5 spectrophotometer. Initial velocities versus substrate
concentration were fit using Prism software (Graphpad Software) to determine
parameters Km, KIapp and kcat.

Caspase-7 + DEVD|GK crystallization and x-ray data collection
To prepare caspase-7 with DEVD|GK crystals, protein in a buffer containing 120 mM
NaCl and 20 mM Tris pH 8.0 was concentrated using Millipore Ultrafree 5K NMWL
membrane concentrators (Millipore) to 7.8 mg/mL as assessed by absorbance at 280 nm.
DEVD|GK peptide dissolved in water was added in 4 fold molar excess and incubated for
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one hour. Crystal trays were setup at room temperature and grown in 3.5 µL hanging drop
with mother liquor consisting of 100 mM citrate buffer, 1M LiSO4 1M NaCl in a 2.5:1
ratio of protein to mother liquor. Crystals grew to a maximum of 250 µm in 7 days at 20
degrees. Crystals were cryoprotected in 20% ethylene glycol in mother liquor with a 60
second incubation, then frozen by rapid immersion in liquid N2. Data were collected
using synchrotron radiation at Brookhaven X25 over 300 frames with 1° oscillations and
showed diffraction data to 2.75Å, with frames 1-50, 142, and 175-245 omitted for data
set 1. Data set 2 was collected identically over 275 frames, with frames 105-145 omitted.
Omitted frames were due to high linear R-factor. Data set 3 was collected identically to
data sets 1 and 2 over 70 frames. Indexing, integration and scaling were carried out with
HKL200073. Data for the lower resolution crystals were collected during the same data
collection trip.

Structure determination
Phase information was obtained by molecular replacement using 1F1J as the search
model with residues corresponding to L2' omitted during searches with PHASER115.
Removed residues were rebuilt into unambiguous density using COOT116, then refined
using Refmac117 restrained refinement with TLS enabled and NCS applied to residues 6673, 136-141, 176-186, 233-218. Water and sulfate molecules were inserted manually and
checked for stereochemical appropriateness. The final refined model from data set 1
contains residues 55–185, 214–226, 236–304 for chain A and 54–188, 212– 306 for chain
B. Uncleavable peptide is modeled for residues DEV as chain E, 25 water molecules are
assigned chain O, and 2 sulfates assigned chain S.
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B: EGAD SCRIPTS
Outputs and tabulated output data in excel format can be found on the Hardy linux
workstation solitude in the /home/shared/EGAD directory.

1SHJ_A.input
START
#### Input files ####
# Each of these lines declares the location of an input file
# for the design calculation.
# The PDB file that serves as the template for this monomer
TEMPLATE_PDB
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/1SHJ_A.pdb
# The resparam file that defines prototype residues
RESPARAM_FILE
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/vdw0.90.r
esparam
# The forecfield file that defines atom-specific information,
# such as VDW radii
FORCEFIELD
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/atoms.for
cefield
# The rotamer file that defines the rotamer library
ROTAMER_LIBRARY
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/bbind02_m
ay.rotamers
# The torsion parameter file that defines the torsional correction
# for 1,4 bonded atoms
TORSION_FILE
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/opls.tors
ions
# The SASA points file that defines test points on the unit sphere
# for calculation of SASA.
SASA_POINTS_FILE
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/sasa.txt
#### Energy table file settings ####
# These two parameters instruct the application where to find
# pre-calculated energy tables, and whether to load them or calculate
# them fresh. Calculating fresh tables is recommended, in general.
ENERGY_TABLE
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/tet_caspase
LOAD_ENERGIES
0
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#### Variable position definitions ####
# This section defines which positions will be allowed to mutate
# during the design calculation. Its a simple table of position indices
# (from the PDB file) and the residues allowed at that position.
#
# Any positions not mentioned here are assumed to be "fixed", that is
# to say they will not move during a design. Any positions defined to
# be the same as their wild-type counterpart will be allowed to change
# rotamers.
#
# The special keyword "all" will allow any residue type (except GLY,
# CYS, and PRO).
VARIABLE_POSITIONS
159
all # ILE
211
all # Tyr
213
all # Ile
221
all # PHE
223
TYR # ONLY ROTOMER CHANGE
290
all # CYS
292
all # VAL
END
#### Energy function settings ####
# Each of these flags sets whether a portion of the energy function
# should be used in the design calculation. A '1' means that it will
# be included, while a '0' means it will not.
VDW_FLAG
1
COULOMB_FLAG
1
TORSION_FLAG
1
SASA_FLAG
1
GB_FLAG
1
HBOND_FLAG
0
REFERENCE_FLAG
1
#### Energy function parameters ####
# Various parameters that modify how the energy functions behave.
# At this point, I just use this to define what scaling factor to
# apply to the VDW radius.
VDW_RADII_SCALE
0.90
END
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1SHJ_B.input
START
TEMPLATE_PDB
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/1SHJ_B.pdb
VARIABLE_POSITIONS
159
all
211
all
213
all
221
all
223
TYR
290
all
292
all
END

#
#
#
#
#
#
#

ILE
Tyr
Ile
PHE
ONLY ROTOMER CHANGE
CYS
VAL

END

Dox.liginput
START
PARAMETER_FILE
LOCATION
COORDINATES
SPREAD_RADIUS
SPREAD_GRAIN
XYZ_ROTS
XYZ_RANGE
END_LOCATION

dox.ligparam
53.538
13.249
2.0
3.0
3 3 3
0.195 0.195 0.195

3.811

END

Dox.ligparm
EGAD Ligand Parameter file for Doxycycline
by Arnab Chowdry; edited by Witold Witkowski
8-14-2007
Format Key:
Each LIGAND entry holds the information necessary to define one
ligand.
CORD lines hold atom coordinate information:
Atom Number Atom Name
Atom Type Rigid Body
z
Charge
CORD
1
CA
CT
3
10.616 0.000

x

y

2.340

1.155

CNCT lines hold atom connectivity information, expressed as a list of
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atoms directly connected to the first one:
Parent Atom
Bonded Atoms
CNCT
1
2 4 5 6
ROTB lines hold rotable bond information. Atoms connected to the
first atom (excluding the second atom) will be dependent on the rotable
bond:
First Atom Second Atom
ROTB
START
LIGAND DOX
CORD 1
C
CA
0
52.569 15.775
3.409
0.084104
CORD 2
C
CA
0
53.435 16.652
2.849
0.434036
CORD 3
C
CA
0
54.774 16.229
3.364
0.007574
CORD 4
C
CA
0
54.924 14.645
3.172
0.060912
CORD 5
C
CA
0
53.683 13.942
2.473
0.672938
CORD 6
C
CA
0
52.192 14.519
2.676
-1.551142
CORD 7
C
CA
0
53.795 12.445
2.762
-1.127784
CORD 8
C
CA
0
53.736 12.115
4.245
-0.567027
CORD 9
C
CA
0
54.748 12.933
5.031
0.853653
CORD 10
C
CA
0
55.347 14.009
4.492
0.212514
CORD 11
C
CA
0
55.006 12.507
6.420
0.493023
CORD 12
C
CA
0
54.390 11.248
6.895
0.557629
CORD 13
C
CA
0
53.832 10.334
5.986
-0.23334
CORD 14
C
CA
0
53.943 10.603
4.502
-0.57567
CORD 15
C
CA
0
53.224
9.178
6.445
-0.333433
CORD 16
C
CA
0
53.173
8.912
7.812
-0.409527
CORD 17
C
CA
0
53.732
9.788
8.720
-0.022899
CORD 18
C
CA
0
54.348 10.950
8.269
-0.073312
CORD 19
C
CH3
0
50.154 15.356
1.682
-0.405255
CORD 20
C
CN
0
53.503 16.985
1.411
0.573606
CORD 21
C
CH3
0
51.536 13.926
0.302
-0.200686
CORD 22
C
CH3
0
55.273 10.044
3.956
-0.758613
CORD 23
H
HA
0
53.713
9.601
9.774
0.264047
CORD 24
H
HO
0
55.356 12.506
8.863
0.584718
CORD 25
H
HO
0
52.964 11.257
1.338
0.499983
CORD 26
H
HC
0
52.545 13.671
0.028
0.176319
CORD 27
H
HC
0
51.097 14.439 -0.543
0.194366
CORD 28
H
HC
0
50.980 13.010
0.486
0.202262
CORD 29
H
HC
0
49.764 15.781
0.768
0.193855
CORD 30
H
HC
0
49.470 14.575
2.019
0.180426
CORD 31
H
HC
0
50.173 16.138
2.430
0.446138
CORD 32
H
HN
0
51.968 18.326
1.517
0.291143
CORD 33
H
HA
0
53.882 14.106
1.427
0.243309
CORD 34
H
HA
0
51.607 13.843
3.297
0.266719
CORD 35
H
HA
0
54.743 12.117
2.358
0.246798
CORD 36
H
HA
0
52.723 12.328
4.589
0.255958
CORD 37
H
HA
0
53.130 10.087
4.007
0.239156
CORD 38
H
HA
0
52.795
8.485
5.745
0.241564
CORD 39
H
HA
0
52.698
8.017
8.163
0.433676
CORD 40
H
HN
0
52.664 18.115 -0.034
0.554144
CORD 41
H
HO
0
52.374 14.855
5.164
0.569422
CORD 42
H
HO
0
56.723 15.392
4.666
0.212854
CORD 43
H
HC
0
55.387
9.012
4.261
0.225906
CORD 44
H
HC
0
56.126 10.599
4.327
0.173835
CORD 45
H
HC
0
55.301 10.066
2.873
0.542809
CORD 46
H
HO
0
56.012 15.052
1.540
0.447089
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CORD
CORD
CORD
CORD
CORD
CORD
CORD
CORD
CORD
CORD
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT

47
48
49
50
51
52
53
54
55
56
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

N
N
O
O
O
O
O
O
O
O
2
1
2
3
4
1
5
7
8
4
9
11
12
8
13
15
16
12
29
2
26
14
17
53
54
21
21
21
19
19
19
48
5
6
7
8
14
15
16
48
49
50
22
22
22
51
6

N
N
OH
OH
OH
O
OH
OH
O
O

0
0
0
0
0
0
0
0
0
0

6
3
4
5
6
5
8
9
10
9
12
13
14
13
16
17
18
17
30
48
27
43

49
20
56
10
7
34
35
14
11
50
52
18
15
22
38
39
23
53
31
55
28
44

19

21

51.503
52.619
52.741
56.387
56.045
55.639
54.879
52.718
54.419
55.718

51
33
47
54
36

37

47
47
45
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14.842
17.869
15.627
14.606
14.464
13.205
11.754
11.745
16.517
16.888

1.440
0.928
4.741
5.091
2.297
7.222
9.222
2.115
0.708
3.715

-0.873187
-0.51929
-0.591843
-0.5372
0.201514
-0.611946
-0.765921
-0.553176
-0.625366
-0.501389

CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
CNCT
done
STOP

48
49
50
51
52
53
54
55
56

20
1
10
4
11
18
7
20
3

32
41
42
46

40

24
25

Etable.cmdline
allow-wt
egad-input 1SHJ_A.input,1SHJ_B.input
ligand-inputs
dox.liginput

Machines
michael:2
gabriel:2
raphael:2
uziel:2
sariel:2

Monte_carlo.cmdline
random-seed
num-runs
num-saved
num-steps
etable
groups

116200268
100000
1000
10000
dox_caspase.etable
dox_caspase.groups

Montecarlo.sc
#!/bin/bash
# Monte Carlo Minimizer Script, by Witold
echo "Running Minimizer"
echo "Monte Carlo Simulation"
echo monte_carlo.cmdline
mpirun -all-cpus -machinefile machines ~/EGAD_Clients/bin/MPIMonteCarlo
--CLPLoad=monte_carlo.cmdline &> monte_carlo.log &
echo "The script should be running, checking monte_carlo.log for
results"
echo "Push CTRL+C to quit log file"
tail -f monte_carlo.log

Movestuff.sc
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#This copies the important files to a new dir.
#Edit the last bit!!!!!
#Written by Witold, 6-6-07
cp -r ./common_inputs 1SHJ_* dox.* machines *.cmdline *.py *.sc *.pdb
*.pml ../doxdes3.2.27
# rm solu*.*
echo "That Should do it!"
echo "Now remember to edit this file before you run it again!"

Presurf.sc
clear
echo -e "
\E[5mI'm about to delete all the previous surfnet
files\E[25m"
echo "
Push control-c to stop me!"
sleep 1
echo "5"
sleep 1
echo "4"
sleep 1
echo "3"
sleep 1
echo "2"
sleep 1
echo "1"
rm *.srf
rm *.grf
rm surfnet.ps
rm gaps*
rm volumes*
rm *.out
clear
echo -e "
\E[5mRunning Surfnet...\E[25m"
surfnet &> surfnet.out
sleep 7
surface &> surface.out
sleep 5
surfplot &> surfplot.out
sleep 10
clear
echo "
All done"

Print_structuresnue.py
#!/usr/bin/python
#
# This script parses out the result data from a run of MPIMonteCarlo
# and generates command lines for use with MPIPolymerTable. It has
# been modified from previous versions to accept two lists of input
# files: one for proteins and another for ligands.
#
# It also searches for duplicate solutions and removes them from the
# output.
#
import re,sys,os
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if (len(sys.argv) < 3):
print "Please specify a data file to process and associated input
files."
sys.exit(1)
# Maps sequence data to energy
SOLUTIONS = {}
# Maps energy value to 3-letter code sequence
ENERGY_TO_SEQ = {}
# The first file on the command line is an output file from a run of
# MPIMonteCarlo, and should contain result lines that we need to parse
# and store.
find_data = re.compile("^OUTPUT:\s+\[[\d]+\][\s]+([\d\\.]+)\s+((?:[\d]+\.)+)")
find_seq = re.compile("^OUTPUT:\s+\[[\d]+\][\s]+([\d\-\.]+)\s+((?:[AZ]{3}\.)+)")
find_point = re.compile("^ENERGY:\s+([a-zA-Z\s]*) Point Energy is
([\d\-\.]+)")
fp = open(sys.argv[1],'r')
for line in fp.readlines():
match = find_data.match(line)
if match:
SOLUTIONS[match.group(2).replace('.',',')] =
float(match.group(1))
else:
match = find_seq.match(line)
if match:
ENERGY_TO_SEQ[float(match.group(1))] = match.group(2)
fp.close()
# Now we want to sort by energy value. To do this, we reverse the
dictionary
# into a sorted array.
sorted = [(v,k) for k,v in SOLUTIONS.items()]
sorted.sort()
# Open a file to print summary data for the structures generated.
fp = open("print_summary.txt",'w')
i = 0
energy_cats = {}
energy_keys = []
for energy,sol in sorted:
command = "MPIPolymerTable -i " + sys.argv[2] + " -w -p"
sol = sol[:-1]
if (len(sys.argv) > 3):
command += " -l " + sys.argv[3]
else:
split_string = sol.split(",")
sol = ",".join(split_string[:-1])
command += " -c " + sol + " -o solution_" + str(i) + ".pdb"
output = os.popen(command, 'r')
for line in output.readlines():
match = find_point.match(line)
if match:
energy_cats[match.group(1)] = match.group(2)
if i == 0:
# Print headers
fp.write("SOLUTION\tENERGY\tSEQUENCE")
energy_keys = energy_cats.keys()
for key in energy_keys:
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fp.write("\t"+key)
fp.write("\n")
fp.write("solution_" + str(i) +
":\t"+str(energy)+"\t"+ENERGY_TO_SEQ[energy])
for key in energy_keys:
fp.write("\t"+energy_cats[key])
energy_cats[key] = "N/A" # reset for next round
fp.write("\n")
i += 1
if i == 100: break
# Close the summary file
fp.close()

Struct.sc
#!/bin/bash
# Structure Compilation script, By Witold (edited for +/- ligand 5-1608)
# Uses the pthyon script, print_structures.py
echo "Finding Structures!"
python print_structuresnue.py monte_carlo.log 1SHJ_A.input,1SHJ_B.input
echo "Renaming output file to summary_-_ligand.txt"
mv print_summary.txt summary_-_ligand.txt
python print_structuresnue.py monte_carlo.log 1SHJ_A.input,1SHJ_B.input
dox.liginput
echo "Renaming output file to summary_+_ligand.txt"
mv print_summary.txt summary_+_ligand.txt
echo "DONE"

Tabling.sc
#!/bin/bash
# Tabling Script, by Witold
rm etable.log
echo "Running Tabling"
mpirun -all-cpus -machinefile machines
~/EGAD_Clients/bin/MPIPolymerTable --CLPLoad=etable.cmdline &>
etable.log &
echo "The script should be running, I'm printing the log file as it is
written."
echo "push CTRL+C to escape"
tail -f etable.log

Top5.pml
load
load
load
load
load

solution_0.pdb
solution_1.pdb
solution_2.pdb
solution_3.pdb
solution_4.pdb
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# The interesting bits happen here:
remove hydrogen
#load the mutated residues
sele
/solution_0///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148
create Sol_0Mut, sele
delete sele
sele
/solution_1///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148
create Sol_1Mut, sele
delete sele
sele
/solution_2///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148
create Sol_2Mut, sele
delete sele
sele
/solution_3///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148
create Sol_3Mut, sele
delete sele
sele
/solution_4///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148
create Sol_4Mut, sele
delete sele
#load and select interesting residues
#sele ////187+148+160+167+225
#create Pocket, sele
#delete sele
show surface
hide lines
delete sele
create Sol_0Dox, /solution_0///DOX
create Sol_1Dox, /solution_1///DOX
create Sol_2Dox, /solution_2///DOX
create Sol_3Dox, /solution_3///DOX
create Sol_4Dox, /solution_4///DOX
show spheres, Sol_0Dox
show spheres, Sol_1Dox
show spheres, Sol_2Dox
show spheres, Sol_3Dox
show spheres, Sol_4Dox
show dots, Sol_0Dox
show dots, Sol_1Dox
show dots, Sol_2Dox
show dots, Sol_3Dox
show dots, Sol_4Dox
show sticks, Mutated
#show surface, Pocket
show spheres, DOX
sele ////223
create Switch, sele
color red, Switch
show sticks, Switch
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delete sele
load ../1f1J.pdb
align 1f1j, solution_0
hide lines, 1f1j
hide sticks, 1f1j
show cartoon, 1f1j
delete sele
sele /1f1j///223+523
create 1F1J_Tyr, sele
delete sele
color blue, 1F1J_Tyr
show sticks, 1F1J_Tyr
load dox.pdb
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